- Published on
Infectious Disease – Dengue
DENGUE
ESSENTIALS DESCRIPTION
A virus called dengue is spread by mosquitoes and causes a serious sickness that resembles the flu. With a 1–5% patient mortality rate, the virus can occasionally cause potentially fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
The study of epidemiology
The prevalence
• Two-fifths of the world's population, or over 2.5 billion people, are susceptible to infection
The rainy season increases transmission. An estimated 50–100 million infections, including 500,000 DHF cases and 22,000 fatalities, occur globally each year
The frequency
• The virus can be found in tropical regions and
It is endemic in around 100 nations in Asia, the Pacific, the Americas, Africa, and the Caribbean. It is found in subtropical zones, primarily in urban and suburban settings.
RISK ELEMENTS
Visiting or residing in dengue-endemic areas
Genetics
There are no hereditary elements at play.
GENERAL PREVENTION: Steer clear of mosquito bites and stay away from dengue endemic regions.
Wear long sleeves, ideally with permethrin insecticide impregnated. Apply mosquito repellent with at least 30% N,N-diethyl-3-methylbenzamide (DEET) on exposed skin and clothing.
– Because Aedes mosquitoes bite during the day, bed nets are not very effective.
• Vector control: Get rid of mosquitoes indoors by using insecticides; remove standing water from pools to get rid of mosquito breeding grounds.
Apply larvicidal compounds to sources of stagnant water, such as Abate.
Predatory copepods are introduced into stagnant water sources to control biological vectors.
Pathophysiology
• The incubation period for dengue after inoculation is 3–14 days, although it is often 4–7 days
• The virus replicates in dendritic cells; it then infects reticuloendothelial cells, including dendritic cells, hepatocytes, and endothelial cells; it releases immune mediators that influence cellular and humoral responses; the resulting acute febrile illness lasts 5–7 days; the patient recovers fully in 7–10 days; prior exposure to another dengue serotype predisposes the patient to DHF and DSS; and DHF and DSS typically appear between the third and seventh day of illness at the end of the febrile period. Capillary fragility, thrombocytopenia, and disseminated intravascular coagulation (DIC) cause hemorrhages ranging from minor petechiae to potentially fatal gastrointestinal (GI) bleeding; liver damage causes abnormal liver function tests; and increased capillary permeability causes plasma leakage, which leads to hemoconcentration and potential pleural effusions and ascites.
& coagulopathies • Hepatitis caused by Dengue can be lethal
ETIOLOGY The dengue virus belongs to the family Flaviviridae (ssRNA); it has four antigenically unique serotypes (types 1–4); the sole hosts of infection are humans and nonhuman primates; and Aedes mosquitoes, primarily Aedes aegypti and Aedes albopictus, are the vectors of transmission. Considerations for Children
There is evidence of mother-to-child transmission under COMMONLY ASSOCIATED CONDITIONS
History of Diagnosis
• Signs: fever, chills, headache, and myalgias Rash, bone pain following fever onset, nausea, vomiting, cutaneous hyperesthesia, altered taste perception, appetite loss, abdominal discomfort, and hemorrhagic symptoms such as bruising, epistaxis, gingival bleeding, gastrointestinal bleeding, and menorrhagia
• History of travel
PHYSICAL EXAMINATION • Fever • Shock symptoms, such as prolonged capillary refill, tachycardia, and hypotension • Rash: generalized blanching macular rash
Morbilliform maculopapular rash, which spares the palms and soles, is the second type of rash.
– Symptoms of bleeding include petechiae, purpura, epistaxis, gum bleeding, and gastrointestinal bleeding. In 97% of instances, conjunctival injection and pharyngeal injection are used.
Hepatomegaly, generalized lymphadenopathy, bleeding mucosae, and mental state assessment for changes in mental state brought on by encephalopathy—which is a result of cerebral edema and intracranial hemorrhages--
Tests for Diagnosis and Interpretation
Initial laboratory tests
IgG and IgM antibody serology (ELISA); complete blood count; leucopenia, frequently accompanied by lymphopenia; elevated hematocrit; thrombocytopenia; liver function tests; elevated transaminases; low albumin; and chemistry panel
Acidosis, elevated blood urea nitrogen (BUN), and hyponatremia
Low fibrinogen and high fibrin breakdown products in DIC; elevated prothrombin time (PT); elevated activated partial thromboplastin time (APTT); and coagulation screen
Currently unavailable in the clinical context are polymerase chain reaction (PCR) techniques; arterial blood gas in critically unwell patients
Follow-up and Particular Points to Remember
• When there is a significant bleeding, blood must be cross-matched. Blood and other bodily fluid cultures should be carried out as needed to rule out other potential causes of sickness.
Imagining
• Pleural effusion may be seen on a chest radiograph; ultrasound may be used to assess ascites, pericardial effusions, and pleural effusions as needed; CT scan of the head for individuals with altered mental states or low consciousness
Pathological Results
As mentioned in the first lab tests
DIFFERENTIAL DIAGNOSIS: Hepatitis, meningitis, leptospirosis, rickettsial disease, typhoid, malaria, yellow fever, bacterial sepsis, other viral infections (such as influenza, chikungunya, Rift Valley fever, and West Nile), bacterial sepsis, and pre-eclampsia during pregnancy
MEDICATION FOR TREATMENT
There is no particular treatment for DSS, DHF, or dengue fever.
ADDITIONAL MEDICATION
General Measures: • Adequate analgesics and antipyretics should be used; • Avoid aspirin because of the hemorrhagic character of the sickness; • Symptomatic and supportive therapy
Referral issues include: • Cardiologist for patients with pericardial effusions; • Critical care specialist for individuals with DHF or DSS; • Infectious disease specialist
Considering the patient
First Stabilization
Resuscitate using the advanced life support (ALS) protocol; administer oxygen empirically; use a large-bore intravenous catheter; administer intravenous colloids to maintain systolic blood pressure greater than 90 mm Hg; administer therapy for DIC if necessary; use an arterial line for continuous blood pressure monitoring and serial blood gas measurements if necessary; use a urethral catheter to measure urine output if necessary; reverse electrolyte abnormalities and acidosis; and cross-match blood in the event of a major bleeding incident secondary to DHF.
Requirements for Admission
Patients with hemodynamic instability; those with DHF or DSS; those who are hypotensive or in DIC should be admitted to intensive care units (ICUs); otherwise, they should be admitted to a general medicine ward.
IV fluids; fluids used in colloids for resuscitation, such as Gelofusine,
• Ringer's lactate maintenance fluids, such as dextran, hetastarch, and human albumin solution
For patients who are really sick, keep a tight fluid input-output log. Patients who are not awake may require frequent neuro-observations.
The patient must be hemodynamically stable and have preferably fully recovered from their sickness in order to be discharged.
Continuing Care Follow-Up Suggestions
• No particular advice for follow-up
Patients should be informed that they are more likely to develop DHF or DSS if they catch dengue of a different serotype. Cases should be reported to the Department of Public Health.
DIET: No particular diet is required. Promote the consumption of oral fluids.
Refer to the General Prevention Section on Patient Education.
PROGNOSIS: The majority of individuals with dengue fever recover completely, and the prognosis is excellent.
• Individuals who make it through the crucial phases of DSS and DHF
Neurological symptoms, brain damage from prolonged ischemia in shock or intracranial bleeding, encephalitis/encephalopathy, seizures, neuropathies, Guillain-Barré syndrome, transverse myelitis, myocarditis, and liver failure are among the conditions that typically resolve without any long-term effects.
DENGUE
ESSENTIALS DESCRIPTION
A virus called dengue is spread by mosquitoes and causes a serious sickness that resembles the flu. With a 1–5% patient mortality rate, the virus can occasionally cause potentially fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
The study of epidemiology
The prevalence
• Two-fifths of the world's population, or over 2.5 billion people, are susceptible to infection
The rainy season increases transmission. An estimated 50–100 million infections, including 500,000 DHF cases and 22,000 fatalities, occur globally each year
The frequency
• The virus can be found in tropical regions and
It is endemic in around 100 nations in Asia, the Pacific, the Americas, Africa, and the Caribbean. It is found in subtropical zones, primarily in urban and suburban settings.
RISK ELEMENTS
Visiting or residing in dengue-endemic areas
Genetics
There are no hereditary elements at play.
GENERAL PREVENTION: Steer clear of mosquito bites and stay away from dengue endemic regions.
Wear long sleeves, ideally with permethrin insecticide impregnated. Apply mosquito repellent with at least 30% N,N-diethyl-3-methylbenzamide (DEET) on exposed skin and clothing.
– Because Aedes mosquitoes bite during the day, bed nets are not very effective.
• Vector control: Get rid of mosquitoes indoors by using insecticides; remove standing water from pools to get rid of mosquito breeding grounds.
Apply larvicidal compounds to sources of stagnant water, such as Abate.
Predatory copepods are introduced into stagnant water sources to control biological vectors.
Pathophysiology
• The incubation period for dengue after inoculation is 3–14 days, although it is often 4–7 days
• The virus replicates in dendritic cells; it then infects reticuloendothelial cells, including dendritic cells, hepatocytes, and endothelial cells; it releases immune mediators that influence cellular and humoral responses; the resulting acute febrile illness lasts 5–7 days; the patient recovers fully in 7–10 days; prior exposure to another dengue serotype predisposes the patient to DHF and DSS; and DHF and DSS typically appear between the third and seventh day of illness at the end of the febrile period. Capillary fragility, thrombocytopenia, and disseminated intravascular coagulation (DIC) cause hemorrhages ranging from minor petechiae to potentially fatal gastrointestinal (GI) bleeding; liver damage causes abnormal liver function tests; and increased capillary permeability causes plasma leakage, which leads to hemoconcentration and potential pleural effusions and ascites.
& coagulopathies • Hepatitis caused by Dengue can be lethal
ETIOLOGY The dengue virus belongs to the family Flaviviridae (ssRNA); it has four antigenically unique serotypes (types 1–4); the sole hosts of infection are humans and nonhuman primates; and Aedes mosquitoes, primarily Aedes aegypti and Aedes albopictus, are the vectors of transmission. Considerations for Children
There is evidence of mother-to-child transmission under COMMONLY ASSOCIATED CONDITIONS
History of Diagnosis
• Signs: fever, chills, headache, and myalgias Rash, bone pain following fever onset, nausea, vomiting, cutaneous hyperesthesia, altered taste perception, appetite loss, abdominal discomfort, and hemorrhagic symptoms such as bruising, epistaxis, gingival bleeding, gastrointestinal bleeding, and menorrhagia
• History of travel
PHYSICAL EXAMINATION • Fever • Shock symptoms, such as prolonged capillary refill, tachycardia, and hypotension • Rash: generalized blanching macular rash
Morbilliform maculopapular rash, which spares the palms and soles, is the second type of rash.
– Symptoms of bleeding include petechiae, purpura, epistaxis, gum bleeding, and gastrointestinal bleeding. In 97% of instances, conjunctival injection and pharyngeal injection are used.
Hepatomegaly, generalized lymphadenopathy, bleeding mucosae, and mental state assessment for changes in mental state brought on by encephalopathy—which is a result of cerebral edema and intracranial hemorrhages--
Tests for Diagnosis and Interpretation
Initial laboratory tests
IgG and IgM antibody serology (ELISA); complete blood count; leucopenia, frequently accompanied by lymphopenia; elevated hematocrit; thrombocytopenia; liver function tests; elevated transaminases; low albumin; and chemistry panel
Acidosis, elevated blood urea nitrogen (BUN), and hyponatremia
Low fibrinogen and high fibrin breakdown products in DIC; elevated prothrombin time (PT); elevated activated partial thromboplastin time (APTT); and coagulation screen
Currently unavailable in the clinical context are polymerase chain reaction (PCR) techniques; arterial blood gas in critically unwell patients
Follow-up and Particular Points to Remember
• When there is a significant bleeding, blood must be cross-matched. Blood and other bodily fluid cultures should be carried out as needed to rule out other potential causes of sickness.
Imagining
• Pleural effusion may be seen on a chest radiograph; ultrasound may be used to assess ascites, pericardial effusions, and pleural effusions as needed; CT scan of the head for individuals with altered mental states or low consciousness
Pathological Results
As mentioned in the first lab tests
DIFFERENTIAL DIAGNOSIS: Hepatitis, meningitis, leptospirosis, rickettsial disease, typhoid, malaria, yellow fever, bacterial sepsis, other viral infections (such as influenza, chikungunya, Rift Valley fever, and West Nile), bacterial sepsis, and pre-eclampsia during pregnancy
MEDICATION FOR TREATMENT
There is no particular treatment for DSS, DHF, or dengue fever.
ADDITIONAL MEDICATION
General Measures: • Adequate analgesics and antipyretics should be used; • Avoid aspirin because of the hemorrhagic character of the sickness; • Symptomatic and supportive therapy
Referral issues include: • Cardiologist for patients with pericardial effusions; • Critical care specialist for individuals with DHF or DSS; • Infectious disease specialist
Considering the patient
First Stabilization
Resuscitate using the advanced life support (ALS) protocol; administer oxygen empirically; use a large-bore intravenous catheter; administer intravenous colloids to maintain systolic blood pressure greater than 90 mm Hg; administer therapy for DIC if necessary; use an arterial line for continuous blood pressure monitoring and serial blood gas measurements if necessary; use a urethral catheter to measure urine output if necessary; reverse electrolyte abnormalities and acidosis; and cross-match blood in the event of a major bleeding incident secondary to DHF.
Requirements for Admission
Patients with hemodynamic instability; those with DHF or DSS; those who are hypotensive or in DIC should be admitted to intensive care units (ICUs); otherwise, they should be admitted to a general medicine ward.
IV fluids; fluids used in colloids for resuscitation, such as Gelofusine,
• Ringer's lactate maintenance fluids, such as dextran, hetastarch, and human albumin solution
For patients who are really sick, keep a tight fluid input-output log. Patients who are not awake may require frequent neuro-observations.
The patient must be hemodynamically stable and have preferably fully recovered from their sickness in order to be discharged.
Continuing Care Follow-Up Suggestions
• No particular advice for follow-up
Patients should be informed that they are more likely to develop DHF or DSS if they catch dengue of a different serotype. Cases should be reported to the Department of Public Health.
DIET: No particular diet is required. Promote the consumption of oral fluids.
Refer to the General Prevention Section on Patient Education.
PROGNOSIS: The majority of individuals with dengue fever recover completely, and the prognosis is excellent.
• Individuals who make it through the crucial phases of DSS and DHF
Neurological symptoms, brain damage from prolonged ischemia in shock or intracranial bleeding, encephalitis/encephalopathy, seizures, neuropathies, Guillain-Barré syndrome, transverse myelitis, myocarditis, and liver failure are among the conditions that typically resolve without any long-term effects.
- Published on
Infection Disease – Cytomegalovirus Infection
CYTOMEGALOVIRUS INFECTION
ESSENTIALS DESCRIPTION
A collection of cytomegalovirus-induced infections of various organs and systems (CMV)
The study of epidemiology
The prevalence
• An estimated 27,000 new CMV infections among seronegative pregnant women occur annually in the United States; the rate of infection among individuals aged 10–49 is estimated to be 1.6 infections per 100 susceptible persons annually.
Prevalence: CMV is a prevalent human infection that impacts individuals all over the world.
• Higher CMV seroprevalence is linked to older age and lower socioeconomic level.
• Among those above the age of six, the estimated CMV seroprevalence rate in the United States is 60%. Among people over 80, the seroprevalence could be as high as 90%.
RISK ELEMENTS
• •
Immunosuppression increases the risk of developing severe CMV infection symptoms.
Having a CMV mismatch status is the main risk factor for illness in transplant recipients.
When a CMV-seropositive donor (CMV D+/R-) gives an allograft to a CMV-seronegative recipient, this is known as a solid organ transplant (SOT).
When a patient of an allogeneic bone marrow transplant receives a graft from a donor who is CMV-seronegative (CMV D–/R+), there is an increased risk.
Transplant recipients of the pancreas, small intestine, and lung are most vulnerable to infection. Recipients of heart and liver transplants are at intermediate risk. Those who have kidney transplants are at the lowest risk.
application of substances that deplete lymphocytes (e.g., OKT3, anti-thymocyte globulins, and anti-lymphocyte globulin).
acute rejection of allografts. illness caused by graft versus host.
HIV infection with fewer than 50/mm3 CD4 count.
• • • •
OVERALL PREVENTION
• Prophylactic antiviral treatment for recipients with CMV mismatch or CMV seropositive status. A growing issue among CMV D+/R-patients who were given antiviral prophylaxis is late-onset CMV illness.
• Some facilities utilize CMV immunoglobulin to prevent illness in high-risk persons (those who have received intestine and lung transplants and have CMV D+/R).
It is recommended that recipients of CMV-seronegative allogeneic hematopoietic stem cell transplants (AI) receive blood products from CMV-seronegative donors or leukocyte-depleted blood products.
• CMV-related illnesses in HIV infection have significantly decreased as a result of highly active antiretroviral therapy (HAART).
• No vaccination is currently available.
Pathophysiology
• When a CMV-seronegative recipient receives an allograft from a CMV-seropositive donor (CMV D+/R–), primary CMV infection occurs in SOT recipients.
• Reactivation happens when a seropositive recipient's latent virus reactivates during immunosuppressive episodes. Because of pre-existing anti-CMV immunity, the disease is less severe.
• The infection can be categorized as either symptomatic (CMV illness) or asymptomatic (subclinical CMV infection).
• The disease is further subdivided into tissue-invasive disease (disease with end-organ involvement) and CMV syndrome (disease without end-organ involvement).
• End-organ disease poses a special risk to the transplanted organ.
ETIOLOGY
• The herpesvirus category includes the DNA virus known as CMV.
• Like other viruses in the herpes group, CMV can cause latent infection following primary infection.
COMMON CONNECTED CIRCUMSTANCES
AIDS; solid organ transplantation; bone marrow transplantation; and patients with leukemia or lymphoma, which are severe cancer-related cellular immune suppression
History of Diagnosis
• In immunocompetent individuals, CMV may cause an infectious mononucleosis-like illness or be asymptomatic.
• The symptoms of CMV syndrome include fever, malaise, arthralgias, and myalgias.
• The most prevalent end-organ disease is colitis, which manifests as diarrhea and abdominal pain.
• The symptoms of CMV gastritis include nausea, vomiting, and odynophagia.
• The symptoms of pneumonia include fever, coughing, and dyspnea.
• Hepatitis and myocarditis are further symptoms.
A progressive loss of visual acuity brought on by chorioretinitis can lead to blindness. Following the start of HAART, reports of immune reconstitution syndrome have been made.
Lethargy, photophobia, and a severe headache are symptoms of meningoencephalitis.
Most often, HIV-infected patients experience back discomfort with spinal cord involvement (myelitis, polyradiculitis).
MEDICAL EXAMINATION
Splenomegaly, lymphadenopathy, and pharyngitis
• Rubelliform and maculopapular rashes when CMV mononucleosis is present.
• Signs of encephalitis in the pyramidal tract.
• In myeloradiculopathy, descending weakness in the lower limbs accompanied by a loss of deep tendon reflexes.
• Funduscopic observations in cases of retinitis: Peripheral lesions develop into central ones. regions with perivascular exudates that are yellow-white. There could be bleeding.
Tests for Diagnosis and Interpretation
Lab
First laboratory testing
• Anemia, hemolytic anemia, or thrombocytopenia brought on by myelosuppression.
• Atypical lymphocytes are present.
• A positive CMV IgG serology is a sign of latent virus but also indicates antiviral immunity. beneficial for assessing transplant candidates prior to transplantation as well as possible donors.
• Acute CMV infection or reactivation may result in the presence of IgM antibodies against CMV.
Note: Since immunosuppressed individuals are unable to mount an immunological response, serology is usually not helpful in these cases.
• Viral nucleic acid detection and antigenemia assays are currently the recommended diagnostic methods due to their quick turnaround time and great sensitivity.
• There are numerous real-time PCR platforms (2).
• Tagled monoclonal antibodies specific to the CMV pp65 matrix protein in peripheral blood polymorphonuclear leukocytes are used in CMV antigenemia testing. Because leukocytes are absent in neutropenic patients, their usefulness is restricted.
• CMV has been isolated from blood or other bodily fluids or tissues using viral culture. After one to six weeks, cytotoxic effects appear.
• The shell vial assay is a variation of viral culture. Results are sent out in a day or two.
Follow-up and Particular Points to Remember
• After two weeks of full-dose treatment, if there are still clinical symptoms and a growing or non-declining viral load, consider a drug-resistant virus.
• It is possible to test for genotypic resistance:
UL97 phosphotransferase mutations cause decreased amounts of the active triphosphorylated substance cause ganciclovir resistance. Less frequently, UL54 DNA polymerase mutations happen as second-step alterations following exposure to cidofovir, foscarnet, or ganciclovir. may cause the three antiviral medications to become resistant to one another.
Imaging: CMV encephalitis: periventricular inflammation or meningeal enhancement on the brain; CMV colitis: thickening of the bowel wall on CT imaging; and CMV pneumonitis: interstitial infiltrates on plain radiography. MRI
Diagnostic Techniques and Other
• Colonoscopy in CMV colitis reveals mucosal erythema, erosions, ulcerations, bleeding, and nodular or polypoid lesions; bronchoscopy with bronchoalveolar lavage/biopsy in CMV pneumonitis
Pathological Results
• Tissue invasion is not always associated with CMV viremia. One way to show CMV in tissue is by histology, immunohistochemistry, or in situ DNA hybridization. Large intranuclear inclusions encircled by a transparent halo are common cytopathic findings. There may also be smaller cytoplasmic inclusions.
DIFFERENTIAL DIAGNOSIS
HIV infection (including abrupt seroconversion), human herpesvirus 6 infection, infectious mononucleosis, toxoplasmosis, viral hepatitis, viral gastroenteritis, cryptosporidiosis, and Clostridium difficile infection
MEDICAL CARE
• CMV syndrome typically resolves on its own in the immunocompetent host and doesn't require medical intervention.
• Antiviral medications should be used vigorously to treat CMV infections in immunocompromised patients.
MEDICATION
First Phrase
• The preferred treatment is ganciclovir (AII). Dosage for induction: 5 mg/kg intravenously twice a day. For renal failure, the dosage is modified.
For mild-to-moderate illness, valganciclovir 900 mg p.o. twice daily may be administered as an induction treatment (3).
• Following a first intravenous ganciclovir induction treatment, valganciclovir is often utilized as a step-down oral medication.
• In AIDS patients with CMV retinitis, a sustained-release intraocular ganciclovir implant combined with a systemic drug works better than intravenous treatment alone
Line Two
• For ganciclovir-resistant CMV, provide 60 mg/kg intravenously every 8 hours (or 90 mg/kg intravenously every 12 hours) of foscarnet.
For ganciclovir-resistant CMV, a weekly dosage of 5 mg/kg of cidofovir is recommended. If creatinine clearance is less than 55 mL/min, it is contraindicated.
• In cases of low-level ganciclovir resistance, higher doses of ganciclovir (7.5–10 mg/kg i.v. every 12 hours) have been utilized.
ADDITIONAL MEDICATION
Overall Actions
decrease in immunosuppressive medication dosages
Other Treatments
CMV immunoglobulin for pneumonitis (BIII), a severe form of CMV illness
Continuing Care Follow-Up Suggestions
Monitoring of Patients
• Following the start of antiviral therapy, it is beneficial to assess disease activity every week using molecular tests or antigenemia.
• Generally speaking, patients should be treated for at least two to four weeks, ideally until two weeks after their CMV viremia has cleared up. Recurrent illness is linked to a lack of clearance
• It has also been suggested that maintenance therapy, which involves giving antiviral medications at preventative dosages, be used to finish treatment, which typically lasts up to three months.
PROGNOSIS
• A CMV infection can be fatal, particularly in people with impaired immune systems.
• One of the most serious CMV infections, particularly in bone marrow transplant recipients, is pneumonia.
The fatality rate for CMV encephalitis is very significant.
COMPLICATIONS
• Bowel perforation and peritonitis can result with CMV colitis.
• Congestive cardiac failure can result from CMV myocarditis.
• Patients with HIV may experience cauda equina syndrome.
• Effects of indirect CMV on transplant recipients:
Chronic allograft failure and acute allograft rejection
In receivers with the lungs, bronchiolitis obliterans; in recipients with the heart, accelerated vasculopathy - In liver recipients, disappearing bile duct syndrome
Tubulo-interstitial fibrosis and glomerulopathy (in kidney recipients)
• After the decline in rubella incidence brought on by vaccination, congenital CMV infection is the leading cause of congenital abnormalities in developed nations.
• Abortion, fetal jaundice, anemia, and damage to the central nervous system can result from a congenital CMV infection.
CYTOMEGALOVIRUS INFECTION
ESSENTIALS DESCRIPTION
A collection of cytomegalovirus-induced infections of various organs and systems (CMV)
The study of epidemiology
The prevalence
• An estimated 27,000 new CMV infections among seronegative pregnant women occur annually in the United States; the rate of infection among individuals aged 10–49 is estimated to be 1.6 infections per 100 susceptible persons annually.
Prevalence: CMV is a prevalent human infection that impacts individuals all over the world.
• Higher CMV seroprevalence is linked to older age and lower socioeconomic level.
• Among those above the age of six, the estimated CMV seroprevalence rate in the United States is 60%. Among people over 80, the seroprevalence could be as high as 90%.
RISK ELEMENTS
• •
Immunosuppression increases the risk of developing severe CMV infection symptoms.
Having a CMV mismatch status is the main risk factor for illness in transplant recipients.
When a CMV-seropositive donor (CMV D+/R-) gives an allograft to a CMV-seronegative recipient, this is known as a solid organ transplant (SOT).
When a patient of an allogeneic bone marrow transplant receives a graft from a donor who is CMV-seronegative (CMV D–/R+), there is an increased risk.
Transplant recipients of the pancreas, small intestine, and lung are most vulnerable to infection. Recipients of heart and liver transplants are at intermediate risk. Those who have kidney transplants are at the lowest risk.
application of substances that deplete lymphocytes (e.g., OKT3, anti-thymocyte globulins, and anti-lymphocyte globulin).
acute rejection of allografts. illness caused by graft versus host.
HIV infection with fewer than 50/mm3 CD4 count.
• • • •
OVERALL PREVENTION
• Prophylactic antiviral treatment for recipients with CMV mismatch or CMV seropositive status. A growing issue among CMV D+/R-patients who were given antiviral prophylaxis is late-onset CMV illness.
• Some facilities utilize CMV immunoglobulin to prevent illness in high-risk persons (those who have received intestine and lung transplants and have CMV D+/R).
It is recommended that recipients of CMV-seronegative allogeneic hematopoietic stem cell transplants (AI) receive blood products from CMV-seronegative donors or leukocyte-depleted blood products.
• CMV-related illnesses in HIV infection have significantly decreased as a result of highly active antiretroviral therapy (HAART).
• No vaccination is currently available.
Pathophysiology
• When a CMV-seronegative recipient receives an allograft from a CMV-seropositive donor (CMV D+/R–), primary CMV infection occurs in SOT recipients.
• Reactivation happens when a seropositive recipient's latent virus reactivates during immunosuppressive episodes. Because of pre-existing anti-CMV immunity, the disease is less severe.
• The infection can be categorized as either symptomatic (CMV illness) or asymptomatic (subclinical CMV infection).
• The disease is further subdivided into tissue-invasive disease (disease with end-organ involvement) and CMV syndrome (disease without end-organ involvement).
• End-organ disease poses a special risk to the transplanted organ.
ETIOLOGY
• The herpesvirus category includes the DNA virus known as CMV.
• Like other viruses in the herpes group, CMV can cause latent infection following primary infection.
COMMON CONNECTED CIRCUMSTANCES
AIDS; solid organ transplantation; bone marrow transplantation; and patients with leukemia or lymphoma, which are severe cancer-related cellular immune suppression
History of Diagnosis
• In immunocompetent individuals, CMV may cause an infectious mononucleosis-like illness or be asymptomatic.
• The symptoms of CMV syndrome include fever, malaise, arthralgias, and myalgias.
• The most prevalent end-organ disease is colitis, which manifests as diarrhea and abdominal pain.
• The symptoms of CMV gastritis include nausea, vomiting, and odynophagia.
• The symptoms of pneumonia include fever, coughing, and dyspnea.
• Hepatitis and myocarditis are further symptoms.
A progressive loss of visual acuity brought on by chorioretinitis can lead to blindness. Following the start of HAART, reports of immune reconstitution syndrome have been made.
Lethargy, photophobia, and a severe headache are symptoms of meningoencephalitis.
Most often, HIV-infected patients experience back discomfort with spinal cord involvement (myelitis, polyradiculitis).
MEDICAL EXAMINATION
Splenomegaly, lymphadenopathy, and pharyngitis
• Rubelliform and maculopapular rashes when CMV mononucleosis is present.
• Signs of encephalitis in the pyramidal tract.
• In myeloradiculopathy, descending weakness in the lower limbs accompanied by a loss of deep tendon reflexes.
• Funduscopic observations in cases of retinitis: Peripheral lesions develop into central ones. regions with perivascular exudates that are yellow-white. There could be bleeding.
Tests for Diagnosis and Interpretation
Lab
First laboratory testing
• Anemia, hemolytic anemia, or thrombocytopenia brought on by myelosuppression.
• Atypical lymphocytes are present.
• A positive CMV IgG serology is a sign of latent virus but also indicates antiviral immunity. beneficial for assessing transplant candidates prior to transplantation as well as possible donors.
• Acute CMV infection or reactivation may result in the presence of IgM antibodies against CMV.
Note: Since immunosuppressed individuals are unable to mount an immunological response, serology is usually not helpful in these cases.
• Viral nucleic acid detection and antigenemia assays are currently the recommended diagnostic methods due to their quick turnaround time and great sensitivity.
• There are numerous real-time PCR platforms (2).
• Tagled monoclonal antibodies specific to the CMV pp65 matrix protein in peripheral blood polymorphonuclear leukocytes are used in CMV antigenemia testing. Because leukocytes are absent in neutropenic patients, their usefulness is restricted.
• CMV has been isolated from blood or other bodily fluids or tissues using viral culture. After one to six weeks, cytotoxic effects appear.
• The shell vial assay is a variation of viral culture. Results are sent out in a day or two.
Follow-up and Particular Points to Remember
• After two weeks of full-dose treatment, if there are still clinical symptoms and a growing or non-declining viral load, consider a drug-resistant virus.
• It is possible to test for genotypic resistance:
UL97 phosphotransferase mutations cause decreased amounts of the active triphosphorylated substance cause ganciclovir resistance. Less frequently, UL54 DNA polymerase mutations happen as second-step alterations following exposure to cidofovir, foscarnet, or ganciclovir. may cause the three antiviral medications to become resistant to one another.
Imaging: CMV encephalitis: periventricular inflammation or meningeal enhancement on the brain; CMV colitis: thickening of the bowel wall on CT imaging; and CMV pneumonitis: interstitial infiltrates on plain radiography. MRI
Diagnostic Techniques and Other
• Colonoscopy in CMV colitis reveals mucosal erythema, erosions, ulcerations, bleeding, and nodular or polypoid lesions; bronchoscopy with bronchoalveolar lavage/biopsy in CMV pneumonitis
Pathological Results
• Tissue invasion is not always associated with CMV viremia. One way to show CMV in tissue is by histology, immunohistochemistry, or in situ DNA hybridization. Large intranuclear inclusions encircled by a transparent halo are common cytopathic findings. There may also be smaller cytoplasmic inclusions.
DIFFERENTIAL DIAGNOSIS
HIV infection (including abrupt seroconversion), human herpesvirus 6 infection, infectious mononucleosis, toxoplasmosis, viral hepatitis, viral gastroenteritis, cryptosporidiosis, and Clostridium difficile infection
MEDICAL CARE
• CMV syndrome typically resolves on its own in the immunocompetent host and doesn't require medical intervention.
• Antiviral medications should be used vigorously to treat CMV infections in immunocompromised patients.
MEDICATION
First Phrase
• The preferred treatment is ganciclovir (AII). Dosage for induction: 5 mg/kg intravenously twice a day. For renal failure, the dosage is modified.
For mild-to-moderate illness, valganciclovir 900 mg p.o. twice daily may be administered as an induction treatment (3).
• Following a first intravenous ganciclovir induction treatment, valganciclovir is often utilized as a step-down oral medication.
• In AIDS patients with CMV retinitis, a sustained-release intraocular ganciclovir implant combined with a systemic drug works better than intravenous treatment alone
Line Two
• For ganciclovir-resistant CMV, provide 60 mg/kg intravenously every 8 hours (or 90 mg/kg intravenously every 12 hours) of foscarnet.
For ganciclovir-resistant CMV, a weekly dosage of 5 mg/kg of cidofovir is recommended. If creatinine clearance is less than 55 mL/min, it is contraindicated.
• In cases of low-level ganciclovir resistance, higher doses of ganciclovir (7.5–10 mg/kg i.v. every 12 hours) have been utilized.
ADDITIONAL MEDICATION
Overall Actions
decrease in immunosuppressive medication dosages
Other Treatments
CMV immunoglobulin for pneumonitis (BIII), a severe form of CMV illness
Continuing Care Follow-Up Suggestions
Monitoring of Patients
• Following the start of antiviral therapy, it is beneficial to assess disease activity every week using molecular tests or antigenemia.
• Generally speaking, patients should be treated for at least two to four weeks, ideally until two weeks after their CMV viremia has cleared up. Recurrent illness is linked to a lack of clearance
• It has also been suggested that maintenance therapy, which involves giving antiviral medications at preventative dosages, be used to finish treatment, which typically lasts up to three months.
PROGNOSIS
• A CMV infection can be fatal, particularly in people with impaired immune systems.
• One of the most serious CMV infections, particularly in bone marrow transplant recipients, is pneumonia.
The fatality rate for CMV encephalitis is very significant.
COMPLICATIONS
• Bowel perforation and peritonitis can result with CMV colitis.
• Congestive cardiac failure can result from CMV myocarditis.
• Patients with HIV may experience cauda equina syndrome.
• Effects of indirect CMV on transplant recipients:
Chronic allograft failure and acute allograft rejection
In receivers with the lungs, bronchiolitis obliterans; in recipients with the heart, accelerated vasculopathy - In liver recipients, disappearing bile duct syndrome
Tubulo-interstitial fibrosis and glomerulopathy (in kidney recipients)
• After the decline in rubella incidence brought on by vaccination, congenital CMV infection is the leading cause of congenital abnormalities in developed nations.
• Abortion, fetal jaundice, anemia, and damage to the central nervous system can result from a congenital CMV infection.
- Published on
Infectious Disease - Cystitis
CYSTITIS
ESSENTIALS DESCRIPTION
Both men and women can get cystitis, a lower urinary tract infection (UTI) that affects the bladder.
The study of epidemiology
The prevalence
• In the US, there are 7 million UTI cases each year.
• Roughly one-third of women aged 24 and older will experience at least one UTI episode that necessitates antibiotic therapy (1).
• Within the first year, around half of the women whose simple UTIs go away on their own will get another UTI (2).
The frequency
more common in young women (20% vs. 0.5%, respectively, ages 16–35) than in young men.
RISK FACTORS • Premenopausal women: spermicide use, diaphragm contraception, increasing parity, diabetes mellitus, pregnancy, obesity, neurologic diseases, history of urinary tract infections, anatomic congenital abnormalities, frequent or recent sexual activity, and medical conditions requiring indwelling or repetitive bladder catheterization (3).
UTI history, vaginal atrophy, inadequate bladder emptying, rectocele, cystocele, urethrocele, uterovaginal prolapse, and type 1 diabetes are all present in postmenopausal women (3).
Men: incontinence, surgery, catheterization, urethral blockage, and prostate hypertrophy.
•
For general prevention, practice good atomic hygiene, refrain from using diaphragms, get regular urine tests in the third trimester of pregnancy, and avoid glycosuria if you have diabetes.
ETIOLOGY • The most frequent cause (~>80%) is Escherichia coli.
Proteus mirabilis, Enterobacter species, Citrobacter species, Serratia species, Klebsiella species, Salmonella species, and Morganella morganii are examples of other Enterobacteriaceae. Pseudomonas aeruginosa is an example of a non-Enterobacteriaceae species.
• Another significant issue is the rise of uropathogens, primarily E. coli, that cause nosocomial and community-acquired cystitis and have a notably high level of resistance because they produce extended-spectrum -lactamases (ESBLs) (4). • Saprophyticus Staphylococcus
History of Diagnosis
• Ten percent of patients have low back discomfort, suprapubic tenderness, murky urine, sudden onset, frequency, urgency, and occasionally bloody or foul-smelling urine.
• Kids: General symptoms (diarrhea, vomiting, fever, etc.)
• Older adults: Few symptoms
MEDICAL EXAMINATION
Tenderness in the suprapubic region
Tests for Diagnosis and Interpretation Lab
Urine microscopy, urine culture, and urinary dipstick testing (which detects nitrites and leukocyte esterase in the urine)
• Examine if a pregnancy test is required.
Imagining
• Male ultrasound
• If a young woman experiences recurrent episodes unrelated to coitus or does not respond to antibiotic treatment (as indicated by in vitro antibiotic susceptibility data), consider ultrasonography.
Diagnostic Techniques and Other
Urodynamic examination. Nevertheless, there is little evidence to support the claim that urodynamic testing is helpful in identifying particular urogynecologic mechanisms that would have helped prevent or enhance the medicinal and/or surgical treatment of recurrent UTIs (5).
• Bladder biopsies, cystoscopy, and urography. However, the usefulness of cystoscopy can be regarded as somewhat limited because patients with cystitis rarely experience morphological and/or functional abnormalities of the urinary system (6).
• x-rays of the bladder
DISTINCTIVE DIAGNOSIS
• Contagious: urethritis, vaginitis, silent bacteriuria, and pyelonephritis (upper UTI).
Interstitial cystitis, urolithiasis, bladder tumors, and chronic prostatitis/chronic pelvic pain syndrome are examples of noninfectious conditions.
MEDICATION FOR TREATMENT
Cystitis Recurrent
It has been proposed that a 95% reduction in the risk of recurrence can be achieved by continuous prophylaxis with once-daily treatment with norfloxacin, ciprofloxacin, trimethoprim (TMP), trimethoprim–sulfamethoxazole (TMP-SMX), or nitrofurantoin (8). However, such a strategy needs to be tailored in this day and age due to the startlingly high levels of antibiotic resistance in uropathogens.
Acute Uncomplicated Cystitis • Oral twice daily for three days of trimethoprim-sulfamethoxazole (TMP-SMX): TMP: 160 mg-SMX: 800 mg
• Ciprofloxacin: 250 mg twice daily for three days; Levofloxacin: 250 mg once daily for three days; Norfloxacin: 400 mg twice daily for three days; TMP: 100 mg twice daily for three days; and Fosfomycin tromethamine: 3 g oral single dose (3,7)
• Nitrofurantoin macrocrystals: four times a day, 50–100 mg
for seven days
• 100 mg twice a day for seven days of nitrofurantoin monohydrate macrocrystals (3) Considerations for Pregnancy
For three days, take 250 mg of amoxicillin every eight hours, 100 mg of microcrystalline nitrofurantoin four times a day, and 200 mg of cefpodoxime twice a day. Because it may cause hemolysis in the fetus or newborn, avoid administering it during labor or obstetric delivery as well as in late pregnancy (38–42 weeks). Given that adverse effects appear to be substantially less common in pregnant women treated with fosfomycin than in those treated with other antibiotics, fosfomycin may also be useful in the treatment of cystitis during pregnancy (7).
COMPLEMENTARY & ALTERNATIVE THERAPIES • Probiotics: Studies have demonstrated that Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 are the most effective lactobacilli for preventing urinary tract infections. Significant effectiveness has also been demonstrated by L. crispatus CTV-05 and L. casei shirota. On the
However, it has been demonstrated that L. rhamnosus GG is not as successful in preventing UTIs (9).
• Cranberry juice: It may help treat and/or prevent UTIs because it has been proposed to be a strong inhibitor of bacterial adhesion (10). In example, cranberry juice has been shown to have the potential to lower the number of symptomatic UTIs over a 12-month period, especially for women who experience recurrent UTIs (11).
• Methenamine salts (methenamine hippurate): In individuals without urinary tract abnormalities, methenamine hippurate medication for a brief period of time (≤1 week) has been linked to a significant decrease in symptomatic UTI. Nevertheless, patients with neuropathic bladder or urinary tract disorders do not seem to benefit from them (12).
• Uroanalgesics: The goal of giving uroanalgesics, like phenazopyridine, to individuals who are experiencing acute cystitis symptoms is to alleviate their symptoms. The mucosa of the bladder may experience analgesia from phenazopyridine. Additionally, it has been proposed that its antibacterial action is increased when administered in conjunction with sulfonamides (13). Nonetheless, numerous research indicated that phenazopyridine can be linked to negative side effects, such as
anemia due to hemolysis (14).
• There is still inadequate data to support the idea that intensive hydration can effectively avoid recurrent cystitis.
• There is also mixed evidence about the efficacy of oral and vaginal exogenous estrogens in preventing recurrent UTIs in postmenopausal women (15).
OTHER PROCEDURES AND SURGERY
Surgical correction of urinary tract anatomical defects
PROGNOSIS FOR ONGOING CARE: Most patients with acute, uncomplicated cystitis have a very good prognosis with proper antibiotic treatment.
• Nevertheless, patients without complications or those with risk factors (such anomalies of the urinary system) may experience recurrent cystitis.
Pyelonephritis, urethritis, and mental illnesses, especially following recurrent cystitis
CYSTITIS
ESSENTIALS DESCRIPTION
Both men and women can get cystitis, a lower urinary tract infection (UTI) that affects the bladder.
The study of epidemiology
The prevalence
• In the US, there are 7 million UTI cases each year.
• Roughly one-third of women aged 24 and older will experience at least one UTI episode that necessitates antibiotic therapy (1).
• Within the first year, around half of the women whose simple UTIs go away on their own will get another UTI (2).
The frequency
more common in young women (20% vs. 0.5%, respectively, ages 16–35) than in young men.
RISK FACTORS • Premenopausal women: spermicide use, diaphragm contraception, increasing parity, diabetes mellitus, pregnancy, obesity, neurologic diseases, history of urinary tract infections, anatomic congenital abnormalities, frequent or recent sexual activity, and medical conditions requiring indwelling or repetitive bladder catheterization (3).
UTI history, vaginal atrophy, inadequate bladder emptying, rectocele, cystocele, urethrocele, uterovaginal prolapse, and type 1 diabetes are all present in postmenopausal women (3).
Men: incontinence, surgery, catheterization, urethral blockage, and prostate hypertrophy.
•
For general prevention, practice good atomic hygiene, refrain from using diaphragms, get regular urine tests in the third trimester of pregnancy, and avoid glycosuria if you have diabetes.
ETIOLOGY • The most frequent cause (~>80%) is Escherichia coli.
Proteus mirabilis, Enterobacter species, Citrobacter species, Serratia species, Klebsiella species, Salmonella species, and Morganella morganii are examples of other Enterobacteriaceae. Pseudomonas aeruginosa is an example of a non-Enterobacteriaceae species.
• Another significant issue is the rise of uropathogens, primarily E. coli, that cause nosocomial and community-acquired cystitis and have a notably high level of resistance because they produce extended-spectrum -lactamases (ESBLs) (4). • Saprophyticus Staphylococcus
History of Diagnosis
• Ten percent of patients have low back discomfort, suprapubic tenderness, murky urine, sudden onset, frequency, urgency, and occasionally bloody or foul-smelling urine.
• Kids: General symptoms (diarrhea, vomiting, fever, etc.)
• Older adults: Few symptoms
MEDICAL EXAMINATION
Tenderness in the suprapubic region
Tests for Diagnosis and Interpretation Lab
Urine microscopy, urine culture, and urinary dipstick testing (which detects nitrites and leukocyte esterase in the urine)
• Examine if a pregnancy test is required.
Imagining
• Male ultrasound
• If a young woman experiences recurrent episodes unrelated to coitus or does not respond to antibiotic treatment (as indicated by in vitro antibiotic susceptibility data), consider ultrasonography.
Diagnostic Techniques and Other
Urodynamic examination. Nevertheless, there is little evidence to support the claim that urodynamic testing is helpful in identifying particular urogynecologic mechanisms that would have helped prevent or enhance the medicinal and/or surgical treatment of recurrent UTIs (5).
• Bladder biopsies, cystoscopy, and urography. However, the usefulness of cystoscopy can be regarded as somewhat limited because patients with cystitis rarely experience morphological and/or functional abnormalities of the urinary system (6).
• x-rays of the bladder
DISTINCTIVE DIAGNOSIS
• Contagious: urethritis, vaginitis, silent bacteriuria, and pyelonephritis (upper UTI).
Interstitial cystitis, urolithiasis, bladder tumors, and chronic prostatitis/chronic pelvic pain syndrome are examples of noninfectious conditions.
MEDICATION FOR TREATMENT
Cystitis Recurrent
It has been proposed that a 95% reduction in the risk of recurrence can be achieved by continuous prophylaxis with once-daily treatment with norfloxacin, ciprofloxacin, trimethoprim (TMP), trimethoprim–sulfamethoxazole (TMP-SMX), or nitrofurantoin (8). However, such a strategy needs to be tailored in this day and age due to the startlingly high levels of antibiotic resistance in uropathogens.
Acute Uncomplicated Cystitis • Oral twice daily for three days of trimethoprim-sulfamethoxazole (TMP-SMX): TMP: 160 mg-SMX: 800 mg
• Ciprofloxacin: 250 mg twice daily for three days; Levofloxacin: 250 mg once daily for three days; Norfloxacin: 400 mg twice daily for three days; TMP: 100 mg twice daily for three days; and Fosfomycin tromethamine: 3 g oral single dose (3,7)
• Nitrofurantoin macrocrystals: four times a day, 50–100 mg
for seven days
• 100 mg twice a day for seven days of nitrofurantoin monohydrate macrocrystals (3) Considerations for Pregnancy
For three days, take 250 mg of amoxicillin every eight hours, 100 mg of microcrystalline nitrofurantoin four times a day, and 200 mg of cefpodoxime twice a day. Because it may cause hemolysis in the fetus or newborn, avoid administering it during labor or obstetric delivery as well as in late pregnancy (38–42 weeks). Given that adverse effects appear to be substantially less common in pregnant women treated with fosfomycin than in those treated with other antibiotics, fosfomycin may also be useful in the treatment of cystitis during pregnancy (7).
COMPLEMENTARY & ALTERNATIVE THERAPIES • Probiotics: Studies have demonstrated that Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 are the most effective lactobacilli for preventing urinary tract infections. Significant effectiveness has also been demonstrated by L. crispatus CTV-05 and L. casei shirota. On the
However, it has been demonstrated that L. rhamnosus GG is not as successful in preventing UTIs (9).
• Cranberry juice: It may help treat and/or prevent UTIs because it has been proposed to be a strong inhibitor of bacterial adhesion (10). In example, cranberry juice has been shown to have the potential to lower the number of symptomatic UTIs over a 12-month period, especially for women who experience recurrent UTIs (11).
• Methenamine salts (methenamine hippurate): In individuals without urinary tract abnormalities, methenamine hippurate medication for a brief period of time (≤1 week) has been linked to a significant decrease in symptomatic UTI. Nevertheless, patients with neuropathic bladder or urinary tract disorders do not seem to benefit from them (12).
• Uroanalgesics: The goal of giving uroanalgesics, like phenazopyridine, to individuals who are experiencing acute cystitis symptoms is to alleviate their symptoms. The mucosa of the bladder may experience analgesia from phenazopyridine. Additionally, it has been proposed that its antibacterial action is increased when administered in conjunction with sulfonamides (13). Nonetheless, numerous research indicated that phenazopyridine can be linked to negative side effects, such as
anemia due to hemolysis (14).
• There is still inadequate data to support the idea that intensive hydration can effectively avoid recurrent cystitis.
• There is also mixed evidence about the efficacy of oral and vaginal exogenous estrogens in preventing recurrent UTIs in postmenopausal women (15).
OTHER PROCEDURES AND SURGERY
Surgical correction of urinary tract anatomical defects
PROGNOSIS FOR ONGOING CARE: Most patients with acute, uncomplicated cystitis have a very good prognosis with proper antibiotic treatment.
• Nevertheless, patients without complications or those with risk factors (such anomalies of the urinary system) may experience recurrent cystitis.
Pyelonephritis, urethritis, and mental illnesses, especially following recurrent cystitis
- Published on
Infectious Disease - Cysticercosis
CYSTICERCOSIS
BASICS DESCRIPTION
Taenia solium larvae, which cause cysticercosis, are parasitic infections
• When larvae travel to striated muscle, subcutaneous tissue, and other tissues and critical organs of the body, they develop characteristic cysts (cysticerci), which result in clinical symptoms.
• Many infections are asymptomatic; the most often impacted organs are the skin, heart, skeletal muscle, eyes, and central nervous system (CNS) (neurocysticercosis).
The study of epidemiology
The prevalence
• The most prevalent parasite that causes CNS illness is T. solium.
• In developing nations, it is the leading cause of seizures.
• Up to 10% of all computed tomography (CT) scans in Mexico
Neurocysticercosis is evident on scans at certain institutions.
The frequency
• Globally, more than 50 million persons are infected
• Eastern Europe, Southeast Asia, India, Central and South America, and sub-Saharan Africa have the highest prevalences.
• At least 10% of endemic villages had seropositive results for infection (2).
• In endemic communities, adult T. solium worms may be present in up to 6% of the population at any given time.
RISK ELEMENTS
• Consuming pork that is undercooked or uncooked
• Residencing in unsanitary regions
• Residencing in pig-populated areas, particularly those where pigs have access to human waste
• Inadequate hand hygiene that results in oral and fecal infections (1–5)
Genetics
There are no hereditary elements at play.
OVERALL PREVENTION
• Health education; • Prevent fecal contamination of water, land, and food for humans and animals; • Thoroughly cook pork; Cysticerci are killed when pork is frozen below -5°C (23°F) for longer than four days.
Personal cleanliness and sanitary food preparation
Family members should be screened for illness; cases should be identified and treated right away or in large quantities; pig populations should be treated concurrently; hand washing should be practiced; cleanliness should be improved; strict meat inspection should be followed; and contaminated carcasses should be disposed of properly.
PATHOPHYSIOLOGY: Humans become hosts when they consume T. solium eggs. • Cysticerci grow inside organs and tissue.
• Neurocysticercosis : The majority of neurological symptoms are brought on by immune-mediated inflammation brought on by degenerating cysts. Cysticerci either occupy space or obstruct the flow of cerebrospinal fluid, which results in mass effect symptoms.
• Extraneural cysticercosis: Ocular cysts can develop in the subretinal area, although they typically occur in the vitreous fluid. Damage to retinal tissue or the onset of chronic uveitis are linked to visual impairment.
Skin cysticerci appear as subcutaneous nodules. Nodules may become irritated and painful.
– Although skeletal muscle cysts typically don't cause any symptoms, a high parasite burden can lead to muscular pseudohypertrophy.
– Conduction problems may result from cardiac muscle cysts.
ETIOLOGY
• Human small intestines are the definitive host for adult tapeworms
• Gravid proglottids or eggs are expelled by humans in their stool. – Both male and female reproductive organs are found in proglottids, which are segments of tapeworms. There are 50–60 × 103 viable eggs in each segment.
• The eggs are consumed by the pig, which serves as the intermediate host, and the larvae develop. The pig's bloodstream carries the larvae, which reach elevated concentrations in their muscle.
• When undercooked pork (muscle) is consumed, the head ejaculates and adheres to the new host's intestinal wall. A classic intestinal tapeworm infection results from this.
– The adult T. solium's lifespan is unknown. estimated to be between five and thirty years.
• When humans consume eggs discharged in their feces, they acquire cysticercosis, which is caused by the larval stages.
• The oncospheres that form from the eggs pass through the small intestine.
• Ingestion of eggs might come from another source or as an autoinfection in a patient who already has tapeworm.
COMMON CONNECTED CIRCUMSTANCES
• Strokes, hydrocephalus, epilepsy, and intracranial hypertension
History of Diagnosis
• Sleeplessness, anorexia, and weight loss are among the disease's symptoms.
Pain in the abdomen
Disorders of the digestive system A persistent headache
Seizures, nausea, and vomiting
Neurological symptoms that are focal
Changes in mental state; visual abnormalities or eyesight changes; and skin nodules
Living in or traveling to regions where cysticercosis is widespread; interacting with individuals who have the disease; eating undercooked ham; and asking about worm segments excreted
PHYSICAL EXAMINATION
The following are examples of physical findings:
Fever absence; typically nonfocal neurologic symptoms
The presence of intraocular larvae on ophthalmoscopy may be diagnostic, as can papilledema and reduced retinal venous pulsations.
Meningitis
Visual impairments or nystagmus; hyperreflexia
Sebaceous cyst-like subcutaneous nodules that are palpable
The pseudohypertrophy of muscles
Tests for Diagnosis and Interpretation
Lab
• Serology-full blood count; frequently missing eosinophilia
The enzyme-linked immunosorbent test is very specific and has a 74% sensitivity. As the number of cysts increases, so does sensitivity.
In patients with numerous cysts, the enzyme-linked immunoelectrotransfer blot has a sensitivity of >95% and a specificity of over 100%. Patients with a solitary cyst are poor.
Stool for parasites and ova.
Imaging techniques include soft tissue x-rays, which can reveal calcified cysts, brain CT scans, and brain MRIs, which are the preferred imaging method for detecting brainstem cysts.
Diagnostic Techniques and Other
Both lumbar puncture and biopsy or fine-needle aspiration of subcutaneous nodules are not sensitive or specific. Cerebrospinal fluid may exhibit lymphocytosis, elevated protein, and/or decreased glucose levels when there is severe inflammation.
Pathological Results
Cysts range in size from a few millimeters to 1-2 centimeters and are uniformly round or oval vesicles.
Differential diagnosis, brain tumors, brain abscess, and status epilepticus
These include encephalitis, epidural and subdural infections, meningitis, tuberculosis, hemorrhagic and ischemic strokes, subarachnoid hemorrhage, endophthalmitis, migraine, tension headaches, coccidioidomycosis, toxoplasmosis, and trichomoniasis.
MEDICATION FOR TREATMENT
First Line • Corticosteroids: Prednisone orally or dexamethasone intravenously • Anticonvulsants: Lorazepam, phenytoin, or phenobarbital • Anthelmintics (2): Praziquantel 50 mg/kg/d orally in three divided doses each day for two weeks
For two weeks, take two to three divided doses of second line albendazole (15 mg/kg/d) orally.
ADDITIONAL MEDICATION
Referral issues: • A referral to a neurologist
Seizures, changes in mental status, and other neurological symptoms
Referral to a neurosurgeon for surgical intervention to lower intracranial pressure; Referral to an ophthalmologist for changes in vision or visual problems
OTHER PROCEDURES AND SURGERY
• Interventricular shunt • Ventriculoperitoneal shunt
IN-PATIENT CONSIDERATIONS
• Burr hole to reduce intracranial pressure
First Stabilization
As needed, resuscitation in accordance with the Acute Life Support procedure
Requirements for Admission
• For IV corticosteroid therapy to lower intracranial pressure in patients with status epilepticus
• For patients needing ocular surgery
• For surgical procedures to lower intracranial pressure from obstructive hydrocephalus
Intravenous Fluids
Fluids used for maintenance that contain Ringers lactate
Nursing
Employ the proper barrier nursing strategies.
Criteria for Discharge
• Seizures are stopped; the patient is clinically stable
Continuing Care Follow-Up Suggestions
For patients with chronic CNS calcifications, long-term anticonvulsant treatment
Monitoring of Patients
MRI or follow-up CT scan to evaluate therapy response
A DIET
Before eating, pork should be cooked through.
PATIENT EDUCATION: As mentioned in "General Prevention," patients and their families should understand how to treat seizures with first aid; how to take prescribed drugs; and when to seek medical attention, particularly when to look for symptoms of elevated intracranial pressure or localized
neurologic complaints: People who have recently experienced seizures shouldn't drive, use heavy equipment, climb ladders, swim, or engage in other risky activities.
PROGNOSIS
With the right diagnosis and care, the prognosis is typically excellent.
problems include: loss of eyesight; status epilepticus; stroke; intracranial herniation; long-term anticonvulsant use; and intraventricular shunt problems.
CYSTICERCOSIS
BASICS DESCRIPTION
Taenia solium larvae, which cause cysticercosis, are parasitic infections
• When larvae travel to striated muscle, subcutaneous tissue, and other tissues and critical organs of the body, they develop characteristic cysts (cysticerci), which result in clinical symptoms.
• Many infections are asymptomatic; the most often impacted organs are the skin, heart, skeletal muscle, eyes, and central nervous system (CNS) (neurocysticercosis).
The study of epidemiology
The prevalence
• The most prevalent parasite that causes CNS illness is T. solium.
• In developing nations, it is the leading cause of seizures.
• Up to 10% of all computed tomography (CT) scans in Mexico
Neurocysticercosis is evident on scans at certain institutions.
The frequency
• Globally, more than 50 million persons are infected
• Eastern Europe, Southeast Asia, India, Central and South America, and sub-Saharan Africa have the highest prevalences.
• At least 10% of endemic villages had seropositive results for infection (2).
• In endemic communities, adult T. solium worms may be present in up to 6% of the population at any given time.
RISK ELEMENTS
• Consuming pork that is undercooked or uncooked
• Residencing in unsanitary regions
• Residencing in pig-populated areas, particularly those where pigs have access to human waste
• Inadequate hand hygiene that results in oral and fecal infections (1–5)
Genetics
There are no hereditary elements at play.
OVERALL PREVENTION
• Health education; • Prevent fecal contamination of water, land, and food for humans and animals; • Thoroughly cook pork; Cysticerci are killed when pork is frozen below -5°C (23°F) for longer than four days.
Personal cleanliness and sanitary food preparation
Family members should be screened for illness; cases should be identified and treated right away or in large quantities; pig populations should be treated concurrently; hand washing should be practiced; cleanliness should be improved; strict meat inspection should be followed; and contaminated carcasses should be disposed of properly.
PATHOPHYSIOLOGY: Humans become hosts when they consume T. solium eggs. • Cysticerci grow inside organs and tissue.
• Neurocysticercosis : The majority of neurological symptoms are brought on by immune-mediated inflammation brought on by degenerating cysts. Cysticerci either occupy space or obstruct the flow of cerebrospinal fluid, which results in mass effect symptoms.
• Extraneural cysticercosis: Ocular cysts can develop in the subretinal area, although they typically occur in the vitreous fluid. Damage to retinal tissue or the onset of chronic uveitis are linked to visual impairment.
Skin cysticerci appear as subcutaneous nodules. Nodules may become irritated and painful.
– Although skeletal muscle cysts typically don't cause any symptoms, a high parasite burden can lead to muscular pseudohypertrophy.
– Conduction problems may result from cardiac muscle cysts.
ETIOLOGY
• Human small intestines are the definitive host for adult tapeworms
• Gravid proglottids or eggs are expelled by humans in their stool. – Both male and female reproductive organs are found in proglottids, which are segments of tapeworms. There are 50–60 × 103 viable eggs in each segment.
• The eggs are consumed by the pig, which serves as the intermediate host, and the larvae develop. The pig's bloodstream carries the larvae, which reach elevated concentrations in their muscle.
• When undercooked pork (muscle) is consumed, the head ejaculates and adheres to the new host's intestinal wall. A classic intestinal tapeworm infection results from this.
– The adult T. solium's lifespan is unknown. estimated to be between five and thirty years.
• When humans consume eggs discharged in their feces, they acquire cysticercosis, which is caused by the larval stages.
• The oncospheres that form from the eggs pass through the small intestine.
• Ingestion of eggs might come from another source or as an autoinfection in a patient who already has tapeworm.
COMMON CONNECTED CIRCUMSTANCES
• Strokes, hydrocephalus, epilepsy, and intracranial hypertension
History of Diagnosis
• Sleeplessness, anorexia, and weight loss are among the disease's symptoms.
Pain in the abdomen
Disorders of the digestive system A persistent headache
Seizures, nausea, and vomiting
Neurological symptoms that are focal
Changes in mental state; visual abnormalities or eyesight changes; and skin nodules
Living in or traveling to regions where cysticercosis is widespread; interacting with individuals who have the disease; eating undercooked ham; and asking about worm segments excreted
PHYSICAL EXAMINATION
The following are examples of physical findings:
Fever absence; typically nonfocal neurologic symptoms
The presence of intraocular larvae on ophthalmoscopy may be diagnostic, as can papilledema and reduced retinal venous pulsations.
Meningitis
Visual impairments or nystagmus; hyperreflexia
Sebaceous cyst-like subcutaneous nodules that are palpable
The pseudohypertrophy of muscles
Tests for Diagnosis and Interpretation
Lab
• Serology-full blood count; frequently missing eosinophilia
The enzyme-linked immunosorbent test is very specific and has a 74% sensitivity. As the number of cysts increases, so does sensitivity.
In patients with numerous cysts, the enzyme-linked immunoelectrotransfer blot has a sensitivity of >95% and a specificity of over 100%. Patients with a solitary cyst are poor.
Stool for parasites and ova.
Imaging techniques include soft tissue x-rays, which can reveal calcified cysts, brain CT scans, and brain MRIs, which are the preferred imaging method for detecting brainstem cysts.
Diagnostic Techniques and Other
Both lumbar puncture and biopsy or fine-needle aspiration of subcutaneous nodules are not sensitive or specific. Cerebrospinal fluid may exhibit lymphocytosis, elevated protein, and/or decreased glucose levels when there is severe inflammation.
Pathological Results
Cysts range in size from a few millimeters to 1-2 centimeters and are uniformly round or oval vesicles.
Differential diagnosis, brain tumors, brain abscess, and status epilepticus
These include encephalitis, epidural and subdural infections, meningitis, tuberculosis, hemorrhagic and ischemic strokes, subarachnoid hemorrhage, endophthalmitis, migraine, tension headaches, coccidioidomycosis, toxoplasmosis, and trichomoniasis.
MEDICATION FOR TREATMENT
First Line • Corticosteroids: Prednisone orally or dexamethasone intravenously • Anticonvulsants: Lorazepam, phenytoin, or phenobarbital • Anthelmintics (2): Praziquantel 50 mg/kg/d orally in three divided doses each day for two weeks
For two weeks, take two to three divided doses of second line albendazole (15 mg/kg/d) orally.
ADDITIONAL MEDICATION
Referral issues: • A referral to a neurologist
Seizures, changes in mental status, and other neurological symptoms
Referral to a neurosurgeon for surgical intervention to lower intracranial pressure; Referral to an ophthalmologist for changes in vision or visual problems
OTHER PROCEDURES AND SURGERY
• Interventricular shunt • Ventriculoperitoneal shunt
IN-PATIENT CONSIDERATIONS
• Burr hole to reduce intracranial pressure
First Stabilization
As needed, resuscitation in accordance with the Acute Life Support procedure
Requirements for Admission
• For IV corticosteroid therapy to lower intracranial pressure in patients with status epilepticus
• For patients needing ocular surgery
• For surgical procedures to lower intracranial pressure from obstructive hydrocephalus
Intravenous Fluids
Fluids used for maintenance that contain Ringers lactate
Nursing
Employ the proper barrier nursing strategies.
Criteria for Discharge
• Seizures are stopped; the patient is clinically stable
Continuing Care Follow-Up Suggestions
For patients with chronic CNS calcifications, long-term anticonvulsant treatment
Monitoring of Patients
MRI or follow-up CT scan to evaluate therapy response
A DIET
Before eating, pork should be cooked through.
PATIENT EDUCATION: As mentioned in "General Prevention," patients and their families should understand how to treat seizures with first aid; how to take prescribed drugs; and when to seek medical attention, particularly when to look for symptoms of elevated intracranial pressure or localized
neurologic complaints: People who have recently experienced seizures shouldn't drive, use heavy equipment, climb ladders, swim, or engage in other risky activities.
PROGNOSIS
With the right diagnosis and care, the prognosis is typically excellent.
problems include: loss of eyesight; status epilepticus; stroke; intracranial herniation; long-term anticonvulsant use; and intraventricular shunt problems.
- Published on
Infectious Disease - Cryptoporidiosis
ESSENTIALS DESCRIPTION
An internal protozoan called Cryptosporidium causes self-limited diarrhea in adults and children as well as prolonged or even fatal diarrhea in HIV-infected patients.
The study of epidemiology
The prevalence
In the United States, the condition affects about 300,000 people annually.
The frequency
• The organism is widely distributed throughout the world; seroprevalence rates can reach up to 75% in underdeveloped nations and 25% in industrialized nations; and elevated transmission is observed in temperate regions.
• In the US, there have been reports of significant waterborne epidemics linked to tainted water sources during warmer months (e.g., Milwaukee, WI).
• Dairy farms and other farms with livestock have been mostly responsible for the poisoning of water systems.
Risk factors include: AIDS patients with chronic diarrhea and a CD4 count less than 100 cells/μL; other immunosuppressive conditions; and children under five in impoverished nations. • Those who handle animals
GENERAL PREVENTION Several measures are advised for those infected with HIV, such as the following:
Steer clear of drinking from pools, rivers, or streams.
Avoiding contact with human or animal excrement; avoiding ingesting water while swimming. Particular caution must be used while handling farm animals or soil that may have been tainted by animal waste.
• It is important to check for Cryptosporidium in the stools of pets who have diarrhea.
• Most water purification techniques, including chlorination, are ineffective against the bacterium.
• When traveling to impoverished nations, stay away from drinking tap water.
• The most effective technique for removing oocysts seems to be filtration. Drinking water can be heated for one minute or filtered to 1 μ.
• Although bottled water may be safer than tap water, purity is not guaranteed and the filtering method may differ among brands.
• Drinks with carbonation are safe.
Pathophysiology
• The intracellular protozoan Cryptosporidium can infect cells that are derived from the epithelium.
• Human gastrointestinal and respiratory cells are among the impacted cells.
• One person goes through the whole life cycle.
• Ingestion of oocysts from water tainted with feces typically results in infection.
• Oocysts can endure in the environment for up to 18 months.
• Research has indicated that consuming fewer than 1000 oocysts may result in illness.
• The pathogen spreads directly from one person to another.
• Other ways that infections might spread include through the
as follows:
Pets, daycare facilities, and hospitals
Intercourse
- Pools
ETIOLOGY • C. hominis • C. meleagridis • C. parvum (most prevalent)
History of Diagnosis
• The incubation period lasts seven to ten days.
• In immunocompetent people, watery diarrhea can range in intensity from two days to a month.
• Abdominal cramps may be experienced by patients.
• There could be a low-grade temperature.
• Less likely than other diarrheal causes to induce vomiting.
• Voluminous diarrhea, up to 15 L/d, can occur in a small percentage of people with immunosuppression, such as HIV infection (mostly in those with CD4 count <50 cells />mu;L).
• Loss of weight with prolonged diarrhea.
Up to 40% of patients may experience a recurrence of the disease. Dyspnea is one of the respiratory symptoms.
Physical examination: Nonspecific results
• Malabsorption wastage
Diagnostic Examination and Interpretation Laboratory
• Giemsa-stained oocysts are seen in stool specimens.
• Round oocysts dyed red or pink against a blue-green backdrop are visible with modified acid-fast stains.
• Assays for antigen detection are more sensitive: The gold standard for feces or tissue specimen staining is now immunofluorescent antibody staining. There are also immunochromatographic or ELISA techniques available.
To find the DNA of C. parvum, use the PCR test.
Leukocytosis is uncommon.
• There are no erythrocytes or leukocytes in the feces.
• Absorption of fat is compromised.
• The majority of patients have abnormal D-Xylose testing.
• Tests for liver function usually reveal increased alkaline phosphatase.
• Low vitamin B12 levels are possible.
Imagining
• Bowel wall edema and an ileus pattern may be seen on radiographs. The results are not specific.
• Biliary involvement: The intrahepatic and extrahepatic bile ducts are dilated or irregular.
• Bilateral pulmonary infiltrates indicate respiratory involvement.
Pathological Results
An intracellular, extracytoplasmic parasite is seen protruding from the mucosal surface's brush boundary in a small intestinal sample.
DIFFERENTIAL DIAGNOSIS • Infections with Clostridium difficile • Salmonella, Shigella, and Campylobacter are examples of enteric bacterial infections
• Mycobacterial infection; • Viral gastroenteritis
• Cytomegalovirus colitis; • Giardia, Cyclospora, Isospora, and Microsporidia infections caused by enteric protozoa
MEDICATION FOR TREATMENT
First Phrase
• Anti-parasitic medications have not been shown to be effective in immunocompromised hosts.
• In patients who are not immunocompromised, nitazoxanide effectively treats diarrhea. Adults and children over the age of twelve can consume 500 mg tablets of nitazoxanide. For three days, 500 mg should be given b.i.d. with food. Nitazoxanide is available as a suspension (powder for reconstitution 100 mg/5 mL) for children aged 1–11. For children ages 1–3, take 100 mg b.i.d. (5 mL) with food for three days; for children ages 4–11, take 200 mg b.i.d. (10 mL) with food for three days. AIDS patients have benefited from the compassionate use of nitazoxanide.Adult dosages ranged from 500 to 1500 mg b.i.d., and treatment is given for at least 14 days in this compassionate use context.
• Oral nonabsorbable aminoglycoside paromomycin has been used with varying degrees of success.For adults aged 25 to
35 mg/kg for two to four weeks in divided dosages. There is no effect of paromomycin on extraintestinal cryptosporidiosis. Combine with antimotility drugs.
• Macrolides that have some activity against Cryptosporidium include azithromycin and clarithromycin.
Line Two
• Azithromycin and paromomycin combined • 600 mg of rifaximin t.i.d. p.o. for 14 days
ADDITIONAL MEDICATION
Overall Actions
• Immunocompetent patients are likely to experience a self-limited sickness that lasts anywhere from a few days to six weeks, during which supportive treatment is provided.
• Supportive care is essential for people with HIV.
Other Treatments
Opiates, loperamide, and diphenoxylate/atropine are examples of antimotility drugs.
• It has been demonstrated that octreotide reduces the production of watery stool without completely eliminating the organism.
• Immune reconstitution using extremely active antiretroviral medications works well for diarrhea in AIDS patients. Note: In vitro, protease inhibitors exhibit anti-cryptosporidial properties.
OTHER PROCEDURES AND SURGERY
In-patient considerations for cholecystectomy for acalculous cholecystitis
Requirements for Admission
Patients who are very dehydrated should be admitted to the hospital, especially kids.
Intravenous Fluids
For patients who are extremely dehydrated, parenteral hydration is used. Add more glucose, bicarbonate, potassium, and sodium.
Continuing Care Follow-Up Suggestions
• There is no need for extra monitoring in immunocompetent patients.
• In patients with HIV or other immunocompromised conditions, aggravation and remission are frequent, although organism eradication is less frequent. Those patients require close monitoring.
DIET: Control undernutrition.
• Steer clear of items that contain lactose because secondary lactose sensitivity is prevalent.
• Supplementing with glutamine may enhance fluid absorption.
PROGNOSIS
illness that goes away on its own in immunocompetent people or in AIDS patients whose CD4 count is greater than 150 cells/μL.
DIFFICULTIES
• Prolonged diarrhea is prevalent and potentially fatal in persons with HIV infection.
• Acalculous cholecystitis and sclerosing cholangitis may result from the organism's involvement of the gallbladder and bile ducts.
• Pancreatitis is possible.
• When the respiratory tract is affected, tracheitis and bronchitis may develop.
ESSENTIALS DESCRIPTION
An internal protozoan called Cryptosporidium causes self-limited diarrhea in adults and children as well as prolonged or even fatal diarrhea in HIV-infected patients.
The study of epidemiology
The prevalence
In the United States, the condition affects about 300,000 people annually.
The frequency
• The organism is widely distributed throughout the world; seroprevalence rates can reach up to 75% in underdeveloped nations and 25% in industrialized nations; and elevated transmission is observed in temperate regions.
• In the US, there have been reports of significant waterborne epidemics linked to tainted water sources during warmer months (e.g., Milwaukee, WI).
• Dairy farms and other farms with livestock have been mostly responsible for the poisoning of water systems.
Risk factors include: AIDS patients with chronic diarrhea and a CD4 count less than 100 cells/μL; other immunosuppressive conditions; and children under five in impoverished nations. • Those who handle animals
GENERAL PREVENTION Several measures are advised for those infected with HIV, such as the following:
Steer clear of drinking from pools, rivers, or streams.
Avoiding contact with human or animal excrement; avoiding ingesting water while swimming. Particular caution must be used while handling farm animals or soil that may have been tainted by animal waste.
• It is important to check for Cryptosporidium in the stools of pets who have diarrhea.
• Most water purification techniques, including chlorination, are ineffective against the bacterium.
• When traveling to impoverished nations, stay away from drinking tap water.
• The most effective technique for removing oocysts seems to be filtration. Drinking water can be heated for one minute or filtered to 1 μ.
• Although bottled water may be safer than tap water, purity is not guaranteed and the filtering method may differ among brands.
• Drinks with carbonation are safe.
Pathophysiology
• The intracellular protozoan Cryptosporidium can infect cells that are derived from the epithelium.
• Human gastrointestinal and respiratory cells are among the impacted cells.
• One person goes through the whole life cycle.
• Ingestion of oocysts from water tainted with feces typically results in infection.
• Oocysts can endure in the environment for up to 18 months.
• Research has indicated that consuming fewer than 1000 oocysts may result in illness.
• The pathogen spreads directly from one person to another.
• Other ways that infections might spread include through the
as follows:
Pets, daycare facilities, and hospitals
Intercourse
- Pools
ETIOLOGY • C. hominis • C. meleagridis • C. parvum (most prevalent)
History of Diagnosis
• The incubation period lasts seven to ten days.
• In immunocompetent people, watery diarrhea can range in intensity from two days to a month.
• Abdominal cramps may be experienced by patients.
• There could be a low-grade temperature.
• Less likely than other diarrheal causes to induce vomiting.
• Voluminous diarrhea, up to 15 L/d, can occur in a small percentage of people with immunosuppression, such as HIV infection (mostly in those with CD4 count <50 cells />mu;L).
• Loss of weight with prolonged diarrhea.
Up to 40% of patients may experience a recurrence of the disease. Dyspnea is one of the respiratory symptoms.
Physical examination: Nonspecific results
• Malabsorption wastage
Diagnostic Examination and Interpretation Laboratory
• Giemsa-stained oocysts are seen in stool specimens.
• Round oocysts dyed red or pink against a blue-green backdrop are visible with modified acid-fast stains.
• Assays for antigen detection are more sensitive: The gold standard for feces or tissue specimen staining is now immunofluorescent antibody staining. There are also immunochromatographic or ELISA techniques available.
To find the DNA of C. parvum, use the PCR test.
Leukocytosis is uncommon.
• There are no erythrocytes or leukocytes in the feces.
• Absorption of fat is compromised.
• The majority of patients have abnormal D-Xylose testing.
• Tests for liver function usually reveal increased alkaline phosphatase.
• Low vitamin B12 levels are possible.
Imagining
• Bowel wall edema and an ileus pattern may be seen on radiographs. The results are not specific.
• Biliary involvement: The intrahepatic and extrahepatic bile ducts are dilated or irregular.
• Bilateral pulmonary infiltrates indicate respiratory involvement.
Pathological Results
An intracellular, extracytoplasmic parasite is seen protruding from the mucosal surface's brush boundary in a small intestinal sample.
DIFFERENTIAL DIAGNOSIS • Infections with Clostridium difficile • Salmonella, Shigella, and Campylobacter are examples of enteric bacterial infections
• Mycobacterial infection; • Viral gastroenteritis
• Cytomegalovirus colitis; • Giardia, Cyclospora, Isospora, and Microsporidia infections caused by enteric protozoa
MEDICATION FOR TREATMENT
First Phrase
• Anti-parasitic medications have not been shown to be effective in immunocompromised hosts.
• In patients who are not immunocompromised, nitazoxanide effectively treats diarrhea. Adults and children over the age of twelve can consume 500 mg tablets of nitazoxanide. For three days, 500 mg should be given b.i.d. with food. Nitazoxanide is available as a suspension (powder for reconstitution 100 mg/5 mL) for children aged 1–11. For children ages 1–3, take 100 mg b.i.d. (5 mL) with food for three days; for children ages 4–11, take 200 mg b.i.d. (10 mL) with food for three days. AIDS patients have benefited from the compassionate use of nitazoxanide.Adult dosages ranged from 500 to 1500 mg b.i.d., and treatment is given for at least 14 days in this compassionate use context.
• Oral nonabsorbable aminoglycoside paromomycin has been used with varying degrees of success.For adults aged 25 to
35 mg/kg for two to four weeks in divided dosages. There is no effect of paromomycin on extraintestinal cryptosporidiosis. Combine with antimotility drugs.
• Macrolides that have some activity against Cryptosporidium include azithromycin and clarithromycin.
Line Two
• Azithromycin and paromomycin combined • 600 mg of rifaximin t.i.d. p.o. for 14 days
ADDITIONAL MEDICATION
Overall Actions
• Immunocompetent patients are likely to experience a self-limited sickness that lasts anywhere from a few days to six weeks, during which supportive treatment is provided.
• Supportive care is essential for people with HIV.
Other Treatments
Opiates, loperamide, and diphenoxylate/atropine are examples of antimotility drugs.
• It has been demonstrated that octreotide reduces the production of watery stool without completely eliminating the organism.
• Immune reconstitution using extremely active antiretroviral medications works well for diarrhea in AIDS patients. Note: In vitro, protease inhibitors exhibit anti-cryptosporidial properties.
OTHER PROCEDURES AND SURGERY
In-patient considerations for cholecystectomy for acalculous cholecystitis
Requirements for Admission
Patients who are very dehydrated should be admitted to the hospital, especially kids.
Intravenous Fluids
For patients who are extremely dehydrated, parenteral hydration is used. Add more glucose, bicarbonate, potassium, and sodium.
Continuing Care Follow-Up Suggestions
• There is no need for extra monitoring in immunocompetent patients.
• In patients with HIV or other immunocompromised conditions, aggravation and remission are frequent, although organism eradication is less frequent. Those patients require close monitoring.
DIET: Control undernutrition.
• Steer clear of items that contain lactose because secondary lactose sensitivity is prevalent.
• Supplementing with glutamine may enhance fluid absorption.
PROGNOSIS
illness that goes away on its own in immunocompetent people or in AIDS patients whose CD4 count is greater than 150 cells/μL.
DIFFICULTIES
• Prolonged diarrhea is prevalent and potentially fatal in persons with HIV infection.
• Acalculous cholecystitis and sclerosing cholangitis may result from the organism's involvement of the gallbladder and bile ducts.
• Pancreatitis is possible.
• When the respiratory tract is affected, tracheitis and bronchitis may develop.
- Published on
Infectious Disease – Common Cold
COMMON COLD BASICS DESCRIPTION
Acute viral infection of the upper respiratory tract
The study of epidemiology
The prevalence
• Two to four colds are reported annually by the average adult.
• Children often report six to ten colds annually.
The frequency
RISK FACTORS
An estimated 1 billion colds occur in the US each year.
• Winter, which causes individuals to congregate inside; • Hand contact with an infected person; • Remaining in a confined space with an infected person
• People with immunocompromised conditions; • Children with undeveloped immune systems
• Psychological stress and smoking enhance susceptibility
GENERAL PREVENTION:
• Wash your hands often; • Avoid touching your nose or eyes.
PATHOPHYSIOLOGY:
A contagious viral infectious disease of the upper respiratory system, it is spread by infected people's aerosol, nasal secretions, or saliva.
• Self-restricting
Etiology
• Coronavirus (10–15%) • Rhinovirus (30–50%)
• Influenza (5–15%)
• Less often are respiratory syncytial virus, adenovirus, enterovirus, metapneumovirus, and parainfluenza.
Acute bronchitis, pharyngitis, pharyngolaryngitis, and rhinorrhea
History of Diagnosis
• 1–3 Rhinorrhea
Sneezing, nasal blockage, laryngitis or throat irritation, coughing, chilliness, and occasionally conjunctivitis, headaches, muscle aches, shivering, and anorexia
PHYSICAL EXAMINATION • Symptoms of upper respiratory tract illness • Fever is unusual
Initial laboratory testing for diagnosis and interpretation
Unless a differential diagnosis is required or problems are expected, no laboratory testing is necessary.
Follow-up and Particular Points to Remember
usually not necessary unless problems are suspected or a differential diagnosis is sought.
Imaging First Step
Not necessary unless problems are suspected or a differential diagnosis is sought.
Follow-up and Particular Points to Remember
Not necessary unless problems are suspected or a differential diagnosis is sought.
Diagnostic/Other Procedures: Usually not necessary
Isolating viruses and directly detecting their antigens
Serology-tests for virus neutralization Sputum and/or throat culture
Testing for influenza viruses
- Nasal discharge culture
DIAGNOSIS DIFFERENTIAL:Infectious
Pneumonia, whooping cough, sinusitis, and influenza are all considered noninfectious.
The condition known as allergic rhinitis
MEDICATION FOR TREATMENT
No antiviral medications with proven benefits
ADDITIONAL MEDICATION
Overall Actions
• Acetaminophen, ibuprofen, and aspirin to treat fever and aches and pains (4)
• Decongestants: Nasal: Rebound effect in individuals who use them for longer than three days; oral: Benefits uncertain
Ipratropium bromide nasal spray: Suggested for both children and adults with nasal congestion; Dextromethorphan: A cough remedy for adults; Antihistamines: First-generation antihistamines to alleviate symptoms in adults
Considerations for Children
• Due to the possibility of Reye's syndrome, children and teenagers should not use aspirin.
• Children should not use codeine, dextromethorphan, or antihistamines.
Referral Issues
Extreme symptoms
Other Treatments
Zinc, vitamin C, and echinacea (5) are not advised for active treatment.
Continuing Care Follow-Up Suggestions
If a cough lasts more than three weeks, it may be a sign of pertussis or pneumonia.
Monitoring of Patients
DIET is typically not necessary.
Drinking lots of water is advised.
PATIENT EDUCATION: Stress that the common cold does not require antibiotics.
Reduce contact with cold-stricken individuals; wash your hands frequently, avoid sharing towels, and drink lots of water. Advise against using nasal drops or sprays excessively as they may create rebound congestion.
• To prevent droplets from spreading, cover your mouth and nose with your arm instead of your hands when you cough or sneeze.
PROGNOSIS
In most cases, the illness is mild and self-limiting.
DIFFICULTIES
Pneumonia, otitis media, sinusitis, pharyngitis, acute bronchitis, and exacerbation of asthma, obstructive sleep apnea, and chronic bronchitis
COMMON COLD BASICS DESCRIPTION
Acute viral infection of the upper respiratory tract
The study of epidemiology
The prevalence
• Two to four colds are reported annually by the average adult.
• Children often report six to ten colds annually.
The frequency
RISK FACTORS
An estimated 1 billion colds occur in the US each year.
• Winter, which causes individuals to congregate inside; • Hand contact with an infected person; • Remaining in a confined space with an infected person
• People with immunocompromised conditions; • Children with undeveloped immune systems
• Psychological stress and smoking enhance susceptibility
GENERAL PREVENTION:
• Wash your hands often; • Avoid touching your nose or eyes.
PATHOPHYSIOLOGY:
A contagious viral infectious disease of the upper respiratory system, it is spread by infected people's aerosol, nasal secretions, or saliva.
• Self-restricting
Etiology
• Coronavirus (10–15%) • Rhinovirus (30–50%)
• Influenza (5–15%)
• Less often are respiratory syncytial virus, adenovirus, enterovirus, metapneumovirus, and parainfluenza.
Acute bronchitis, pharyngitis, pharyngolaryngitis, and rhinorrhea
History of Diagnosis
• 1–3 Rhinorrhea
Sneezing, nasal blockage, laryngitis or throat irritation, coughing, chilliness, and occasionally conjunctivitis, headaches, muscle aches, shivering, and anorexia
PHYSICAL EXAMINATION • Symptoms of upper respiratory tract illness • Fever is unusual
Initial laboratory testing for diagnosis and interpretation
Unless a differential diagnosis is required or problems are expected, no laboratory testing is necessary.
Follow-up and Particular Points to Remember
usually not necessary unless problems are suspected or a differential diagnosis is sought.
Imaging First Step
Not necessary unless problems are suspected or a differential diagnosis is sought.
Follow-up and Particular Points to Remember
Not necessary unless problems are suspected or a differential diagnosis is sought.
Diagnostic/Other Procedures: Usually not necessary
Isolating viruses and directly detecting their antigens
Serology-tests for virus neutralization Sputum and/or throat culture
Testing for influenza viruses
- Nasal discharge culture
DIAGNOSIS DIFFERENTIAL:Infectious
Pneumonia, whooping cough, sinusitis, and influenza are all considered noninfectious.
The condition known as allergic rhinitis
MEDICATION FOR TREATMENT
No antiviral medications with proven benefits
ADDITIONAL MEDICATION
Overall Actions
• Acetaminophen, ibuprofen, and aspirin to treat fever and aches and pains (4)
• Decongestants: Nasal: Rebound effect in individuals who use them for longer than three days; oral: Benefits uncertain
Ipratropium bromide nasal spray: Suggested for both children and adults with nasal congestion; Dextromethorphan: A cough remedy for adults; Antihistamines: First-generation antihistamines to alleviate symptoms in adults
Considerations for Children
• Due to the possibility of Reye's syndrome, children and teenagers should not use aspirin.
• Children should not use codeine, dextromethorphan, or antihistamines.
Referral Issues
Extreme symptoms
Other Treatments
Zinc, vitamin C, and echinacea (5) are not advised for active treatment.
Continuing Care Follow-Up Suggestions
If a cough lasts more than three weeks, it may be a sign of pertussis or pneumonia.
Monitoring of Patients
DIET is typically not necessary.
Drinking lots of water is advised.
PATIENT EDUCATION: Stress that the common cold does not require antibiotics.
Reduce contact with cold-stricken individuals; wash your hands frequently, avoid sharing towels, and drink lots of water. Advise against using nasal drops or sprays excessively as they may create rebound congestion.
• To prevent droplets from spreading, cover your mouth and nose with your arm instead of your hands when you cough or sneeze.
PROGNOSIS
In most cases, the illness is mild and self-limiting.
DIFFICULTIES
Pneumonia, otitis media, sinusitis, pharyngitis, acute bronchitis, and exacerbation of asthma, obstructive sleep apnea, and chronic bronchitis
- Published on
nfectious Disease - CERVICITIS
FUNDAMENTAL DESCRIPTION
Sexually transmitted infection characterized by inflammation of the endocervix and/or ectocervix.
Epidemiology
Prevalence • Common among sexually active adolescent females under 20 years of age • Also observed in young adults aged 20 to 24 years
• A prospective cohort study in the United States with 14,322 young adults aged 18 to 26 years:
The overall prevalence of chlamydial infection was 4.2%.
Women (4.7%) exhibited a higher infection rate than men (3.7%). The incidence was greatest among Black women.
– The overall prevalence of gonorrhea was 0.4%.
The prevalence of coinfection with chlamydial and gonococcal infections was 0.03%.
RISK FACTORS • Recent sexual partner during the last 3 months • Multiple sexual partners within the past 6 months • Sexual partner with several other partners • Irregular use of barrier contraception
GENERAL PREVENTION • Implementation of safe sexual practices • Assessment and treatment of sexual partners
• In instances where medical evaluation, counseling, and partner treatment are unfeasible, patient-delivered therapy serves as an alternative.
• Initiate presumptive treatment when the prevalence of Chlamydia trachomatis or Neisseria gonorrhoeae is elevated, or when adherence to follow-up appointments is considered improbable.
Annual chlamydial screening is advised for all sexually active women aged 25 years or younger, as well as for older women with risk factors, such as having a new or many sex partners.
ETIOLOGY
• Chlamydia trachomatis • Neisseria gonorrhoeae • Mycoplasma hominis, Ureaplasma urealyticum
• Mycoplasma genitalium • Herpes simplex virus • In most instances, no organism is identified • Vaginal infections caused by Trichomonas vaginalis or Candida albicans may extend to the ectocervix • Cytomegalovirus is seldom a causative agent
DIAGNOSTIC HISTORY
• Often asymptomatic • Abnormal vaginal discharge or bleeding, especially post-coitus • Dysuria or increased urinary frequency • Dyspareunia
PHYSICAL EXAMINATION • Presence of yellow exudate in the endocervical canal or on an endocervical swab specimen • Cervical friability observed
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Preliminary laboratory examinations • cultivation of cervical discharge, encompassing cultivation for N. gonorrhoeae utilizing modified Thayer–Martin media.
• Gram staining
Cytological analysis of endocervical mucus specimens:
– The identification of gram-negative, intracellular diplococci in endocervical mucus is strongly indicative of gonococcal infection. It exhibits just 50% sensitivity in mucopurulent cervicitis, but it demonstrates 95% sensitivity in gonococcal urethritis. Microscopic analysis of ectocervical fluid specimens utilizing standard wet-mount saline and potassium hydroxide. Leukorrhea (>10 WBC per high power field in microscopic analysis of vaginal fluid) is linked to chlamydial and gonococcal infections of the cervix.
Nucleic acid amplification testing for Neisseria gonorrhoeae and Chlamydia trachomatis. This can be conducted on an endocervical sample, vaginal swab specimen, or urine.
• In the presence of cervical ulcers or necrotic lesions, conduct testing for genital herpes using PCR, DFA, virus culture, or type-specific serology.
• Women diagnosed with cervicitis should undergo assessment for bacterial vaginosis, trichomoniasis, and pelvic inflammatory disease.
• Caution: Clean the ectocervix with a swab before to collecting the endocervical mucus samples.
Subsequent Actions & Unique
Considerations • The management of sexual partners should be tailored to the diagnosed or suspected infection.
Patients and their sexual partners must refrain from sexual intercourse until therapy is concluded, specifically 7 days following a single-dose regimen or upon completion of a 7-day regimen, to prevent re-infection.
• In HIV-positive women, the management of cervicitis diminishes viral shedding and the likelihood of HIV transmission.
Pediatric Considerations
In pre-adolescent children, sexual abuse should be regarded as a potential source of chlamydial or gonococcal infection.
THERAPEUTIC PHARMACEUTICAL
Presumptive therapy is warranted when there is a significant incidence of C. trachomatis and N. gonorrhoeae in the local community, coupled with a low probability of patient adherence to follow-up appointments. It is advisable to await test findings prior to commencing treatment if the prevalence of C. trachomatis and N. gonorrhoeae is low and adherence to follow-up visits is probable.
Initial Line
• Chlamydia infection:
– Azithromycin 1 g orally, single dosage, or – Doxycycline 100 mg orally twice day for 7 days
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage.
• Targeted therapy for alternative etiologies of cervicitis is warranted.
Second Line •
Chlamydial infection: – Ofloxacin 300 mg orally twice day for 7 days Levofloxacin 500 mg orally once daily for seven days
Erythromycin base 500 mg orally four times daily for seven days
• Gonococcal infection: – Administer Cefixime 400 mg orally as a single dosage.
Cefpodoxime 400 mg orally, one administration
The bactericidal level of oral cephalosporins is neither as elevated nor as prolonged as that of ceftriaxone.
– Fluoroquinolones are contraindicated due to rising incidence of gonococcal resistance.
- Spectinomycin 2 g intramuscularly, single administration
Spectinomycin exhibits limited effectiveness in gonococcal pharyngitis.
– It is important to note that Spectinomycin is not currently produced in the United States.
– A solitary 2 g oral administration of azithromycin is efficacious for uncomplicated urogenital gonococcal infection. It is inadvisable due to gastrointestinal intolerance and expense. Moreover, prolonged low concentrations of the medicine may facilitate the development of resistance.
Considerations for Pregnancy:
Primary Line
• Chlamydial infection: – Azithromycin 1 g orally, single dosage ,or – Amoxicillin 500 mg orally three times daily for 7 days
• Theoretically, amoxicillin may lead to a chronic chlamydial infection instead of achieving a microbiological cure. The clinical evidence available are inadequate to substantiate this worry.
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage. Second Line.
• Chlamydial infection: – Erythromycin base 500 mg orally four times daily for 7 days
Erythromycin base 250 mg orally four times daily for 14 days
Erythromycin ethylsuccinate 800 mg orally four times day for seven days.
Erythromycin ethylsuccinate 400 mg orally four times day for 14 days:
Administer a reduced dosage in cases of gastrointestinal intolerance; fluoroquinolones and tetracyclines are contraindicated.
Erythromycin estolate is contraindicated in pregnancy due to its potential hepatotoxic effects.
• Gonococcal infection: Alternative cephalosporin or spectinomycin
CONTINUING TREATMENT POST-CARE SUGGESTIONS
• A test-of-cure for chlamydial infection is advised solely in the following circumstances:
– If therapy adherence is uncertain – If symptoms continue – If re-infection is suspected – During pregnancy • Follow-up testing should not occur immediately after clinical remission. Non-culture testing for C. trachomatis conducted within three weeks post-successful therapy may yield false-positive results because to the persistent excretion of nonviable organisms.
Patients with simple gonorrhea who have received adequate treatment do not require a test of cure. Patients exhibiting chronic symptoms should undergo culture evaluation for N. gonorrhoeae, and any isolated gonococci must be assessed for antibiotic susceptibility.
• In cases of persistent cervicitis, consider the following: – Re-infection (treat partner) – Bacterial vaginosis • Repeat screening should be contemplated within the initial three to four months post-therapy completion is recommended due to the elevated risk of re-infection, particularly among sexually active teens.
Patient Education: Recommend safe sexual practices.
COMPLICATIONS • Pelvic inflammatory illness • Ectopic pregnancy • Infertility • Chorioamnionitis • Premature rupture of membranes • Puerperal infections
FUNDAMENTAL DESCRIPTION
Sexually transmitted infection characterized by inflammation of the endocervix and/or ectocervix.
Epidemiology
Prevalence • Common among sexually active adolescent females under 20 years of age • Also observed in young adults aged 20 to 24 years
• A prospective cohort study in the United States with 14,322 young adults aged 18 to 26 years:
The overall prevalence of chlamydial infection was 4.2%.
Women (4.7%) exhibited a higher infection rate than men (3.7%). The incidence was greatest among Black women.
– The overall prevalence of gonorrhea was 0.4%.
The prevalence of coinfection with chlamydial and gonococcal infections was 0.03%.
RISK FACTORS • Recent sexual partner during the last 3 months • Multiple sexual partners within the past 6 months • Sexual partner with several other partners • Irregular use of barrier contraception
GENERAL PREVENTION • Implementation of safe sexual practices • Assessment and treatment of sexual partners
• In instances where medical evaluation, counseling, and partner treatment are unfeasible, patient-delivered therapy serves as an alternative.
• Initiate presumptive treatment when the prevalence of Chlamydia trachomatis or Neisseria gonorrhoeae is elevated, or when adherence to follow-up appointments is considered improbable.
Annual chlamydial screening is advised for all sexually active women aged 25 years or younger, as well as for older women with risk factors, such as having a new or many sex partners.
ETIOLOGY
• Chlamydia trachomatis • Neisseria gonorrhoeae • Mycoplasma hominis, Ureaplasma urealyticum
• Mycoplasma genitalium • Herpes simplex virus • In most instances, no organism is identified • Vaginal infections caused by Trichomonas vaginalis or Candida albicans may extend to the ectocervix • Cytomegalovirus is seldom a causative agent
DIAGNOSTIC HISTORY
• Often asymptomatic • Abnormal vaginal discharge or bleeding, especially post-coitus • Dysuria or increased urinary frequency • Dyspareunia
PHYSICAL EXAMINATION • Presence of yellow exudate in the endocervical canal or on an endocervical swab specimen • Cervical friability observed
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Preliminary laboratory examinations • cultivation of cervical discharge, encompassing cultivation for N. gonorrhoeae utilizing modified Thayer–Martin media.
• Gram staining
Cytological analysis of endocervical mucus specimens:
– The identification of gram-negative, intracellular diplococci in endocervical mucus is strongly indicative of gonococcal infection. It exhibits just 50% sensitivity in mucopurulent cervicitis, but it demonstrates 95% sensitivity in gonococcal urethritis. Microscopic analysis of ectocervical fluid specimens utilizing standard wet-mount saline and potassium hydroxide. Leukorrhea (>10 WBC per high power field in microscopic analysis of vaginal fluid) is linked to chlamydial and gonococcal infections of the cervix.
Nucleic acid amplification testing for Neisseria gonorrhoeae and Chlamydia trachomatis. This can be conducted on an endocervical sample, vaginal swab specimen, or urine.
• In the presence of cervical ulcers or necrotic lesions, conduct testing for genital herpes using PCR, DFA, virus culture, or type-specific serology.
• Women diagnosed with cervicitis should undergo assessment for bacterial vaginosis, trichomoniasis, and pelvic inflammatory disease.
• Caution: Clean the ectocervix with a swab before to collecting the endocervical mucus samples.
Subsequent Actions & Unique
Considerations • The management of sexual partners should be tailored to the diagnosed or suspected infection.
Patients and their sexual partners must refrain from sexual intercourse until therapy is concluded, specifically 7 days following a single-dose regimen or upon completion of a 7-day regimen, to prevent re-infection.
• In HIV-positive women, the management of cervicitis diminishes viral shedding and the likelihood of HIV transmission.
Pediatric Considerations
In pre-adolescent children, sexual abuse should be regarded as a potential source of chlamydial or gonococcal infection.
THERAPEUTIC PHARMACEUTICAL
Presumptive therapy is warranted when there is a significant incidence of C. trachomatis and N. gonorrhoeae in the local community, coupled with a low probability of patient adherence to follow-up appointments. It is advisable to await test findings prior to commencing treatment if the prevalence of C. trachomatis and N. gonorrhoeae is low and adherence to follow-up visits is probable.
Initial Line
• Chlamydia infection:
– Azithromycin 1 g orally, single dosage, or – Doxycycline 100 mg orally twice day for 7 days
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage.
• Targeted therapy for alternative etiologies of cervicitis is warranted.
Second Line •
Chlamydial infection: – Ofloxacin 300 mg orally twice day for 7 days Levofloxacin 500 mg orally once daily for seven days
Erythromycin base 500 mg orally four times daily for seven days
• Gonococcal infection: – Administer Cefixime 400 mg orally as a single dosage.
Cefpodoxime 400 mg orally, one administration
The bactericidal level of oral cephalosporins is neither as elevated nor as prolonged as that of ceftriaxone.
– Fluoroquinolones are contraindicated due to rising incidence of gonococcal resistance.
- Spectinomycin 2 g intramuscularly, single administration
Spectinomycin exhibits limited effectiveness in gonococcal pharyngitis.
– It is important to note that Spectinomycin is not currently produced in the United States.
– A solitary 2 g oral administration of azithromycin is efficacious for uncomplicated urogenital gonococcal infection. It is inadvisable due to gastrointestinal intolerance and expense. Moreover, prolonged low concentrations of the medicine may facilitate the development of resistance.
Considerations for Pregnancy:
Primary Line
• Chlamydial infection: – Azithromycin 1 g orally, single dosage ,or – Amoxicillin 500 mg orally three times daily for 7 days
• Theoretically, amoxicillin may lead to a chronic chlamydial infection instead of achieving a microbiological cure. The clinical evidence available are inadequate to substantiate this worry.
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage. Second Line.
• Chlamydial infection: – Erythromycin base 500 mg orally four times daily for 7 days
Erythromycin base 250 mg orally four times daily for 14 days
Erythromycin ethylsuccinate 800 mg orally four times day for seven days.
Erythromycin ethylsuccinate 400 mg orally four times day for 14 days:
Administer a reduced dosage in cases of gastrointestinal intolerance; fluoroquinolones and tetracyclines are contraindicated.
Erythromycin estolate is contraindicated in pregnancy due to its potential hepatotoxic effects.
• Gonococcal infection: Alternative cephalosporin or spectinomycin
CONTINUING TREATMENT POST-CARE SUGGESTIONS
• A test-of-cure for chlamydial infection is advised solely in the following circumstances:
– If therapy adherence is uncertain – If symptoms continue – If re-infection is suspected – During pregnancy • Follow-up testing should not occur immediately after clinical remission. Non-culture testing for C. trachomatis conducted within three weeks post-successful therapy may yield false-positive results because to the persistent excretion of nonviable organisms.
Patients with simple gonorrhea who have received adequate treatment do not require a test of cure. Patients exhibiting chronic symptoms should undergo culture evaluation for N. gonorrhoeae, and any isolated gonococci must be assessed for antibiotic susceptibility.
• In cases of persistent cervicitis, consider the following: – Re-infection (treat partner) – Bacterial vaginosis • Repeat screening should be contemplated within the initial three to four months post-therapy completion is recommended due to the elevated risk of re-infection, particularly among sexually active teens.
Patient Education: Recommend safe sexual practices.
COMPLICATIONS • Pelvic inflammatory illness • Ectopic pregnancy • Infertility • Chorioamnionitis • Premature rupture of membranes • Puerperal infections
- Published on
Infectious Disease – Cat Scratch Disease
CAT-SCRATCH DISEASE (AND BARTONELLA INFECTIONS)
Cat-scratch disease is generally a self-limiting acute condition characterized by regional lymphadenopathy, fever, and systemic symptoms, resulting from Bartonella henselae infection. Other manifestations of B. henselae infection encompass fever of unknown origin, hepatosplenic granulomatous disease, neuroretinitis, and encephalopathy.
Other medically significant Bartonella species comprise: – Bartonella quintana, historically responsible for trench fever, linked with persistent bacteremia, endocarditis, and bacillary angiomatosis. – Bartonella bacilliformis, the etiological agent of Oroya fever.
Epidemiology
Occurrence
The prevalence of cat-scratch disease in the United States is roughly 10 cases per 100,000 person-years, with an estimated 24,000 cases identified annually.
Cat-scratch illness is prevalent globally. In temperate areas, it is seasonal, with the majority of cases occurring from August to January.
Cat-scratch illness manifests in immunocompetent individuals across all age groups, with 80% of cases occurring in those under 21 years old.
Most instances of cat-scratch sickness are self-resolving and linked to regional lymphadenopathy.
B. quintana is considered to be worldwide endemic.
B. bacilliformis infection is transmitted through sand fly bites and is exclusively found at altitudes exceeding 1 km in the Andes mountains.
FACTORS OF RISK
Cats serve as the primary hosts and reservoirs of B. henselae.
Most instances of cat-scratch disease can be directly associated with exposure to cats, particularly kittens or felines infested with fleas. Ninety percent of patients had a history of contact with cats.
- A prior history of cat scratch in 60% of cases.
• Incidences of B. quintana infection have been documented among homeless individuals and those from socioeconomically poor backgrounds. These circumstances render persons susceptible to Pediculus humanus (human body louse), a vector for B. quintana infection.
Patients with advanced HIV infection and other immunocompromised individuals are at elevated risk of
progressive chronic infections induced by B. quintana and B. henselae, encompassing bacillary angiomatosis (vascular lesions) and bacillary peliosis (cystic lesions).
COMPREHENSIVE PREVENTION
The risk of cat-scratch disease can be mitigated by minimizing interactions that could result in scratches, bites, or licks from cats or kittens.
The management of cat fleas may diminish the danger of transmission and may be beneficial in households with immunocompromised individuals.
PATHOPHYSIOLOGY • Bartonella species possess the ability for intracellular persistence and induce inflammation in affected organs.
The inflammatory response in cat-scratch disease leads to localized granuloma development.
ETIOLOGY • Bartonella species are meticulous gram-negative rod-shaped aerobic bacteria. • The predominant cause of cat-scratch disease is B. henselae.
• Additional medically significant Bartonella infections encompass
B. quintana and B. bacilliformis. Numerous additional Bartonella species have been linked to isolated instances of human illness.
FREQUENTLY CO-OCCURRING CONDITIONS
B. henselae and B. quintana induce a unique array of illnesses in HIV infection (see to the preceding section). Chronic infections may also arise in recipients of solid-organ transplants and individuals with hematological malignancies.
HISTORY OF DIAGNOSIS
The primary symptom of cat-scratch disease frequently manifests as a tiny erythematous papule or pustule at the scratch site, which endures for several weeks.
• Consequently, lymph nodes associated with the inoculation site become hypertrophied and sensitive.
Patients with cat-scratch disease may not consistently exhibit fever. Low-grade fever and malaise occur in 30% of patients.
Other indications of cat-scratch disease encompass prolonged fever, neuroretinitis (evidenced by diminished visual acuity or alterations in vision), and encephalopathy (characterized by abnormalities in mental status).
B. henselae bacteremia in individuals infected with HIV is linked to a gradual onset of lethargy, malaise, myalgia, weight loss, recurrent fevers of increasing duration and intensity, and occasionally, headaches. Hepatomegaly may be present.
Trench fever is the quintessential manifestation of B. quintana infection, and its natural progression in healthy individuals has been thoroughly documented. Incubation subsequent to inoculation
may extend from 3 to 38 days before to the typically abrupt emergence of chills and fevers. Afebrile infection represents the least prevalent variant. The accompanying symptoms and signs (e.g., headache, vertigo, retro-orbital pain, conjunctival infection) are all vague.
The physical morphology of bacillary angiomatosis is characterized by subcutaneous or dermal nodules and/or single or numerous dome-shaped papules that are skin-colored or red-to-purple, which may exhibit ulceration, serous or bloody exudate, and crusting. Visceral lesions can be notably striking, both in their quantity and the diversity of their macroscopic appearance.
Bacillary peliosis affects organs characterized by multiple blood-filled cystic formations, varying in size from microscopic to several millimeters.
PHYSICAL EXAM • Regional lymphadenopathy is the predominant physical manifestation in cat-scratch disease, occurring in lymph nodes that drain the inoculation site. • In numerous instances, a tiny granuloma or lesion may be identified at the site of inoculation.
Parinaud’s oculoglandular syndrome occurs in roughly 5% of individuals with cat-scratch disease, characterized by conjunctivitis, conjunctival granuloma, and preauricular lymphadenopathy.
Patients with visceral disease may exhibit hepatosplenomegaly.
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Initial Assessments
In the initial stages of the disease, the total white blood cell count may reveal mild leukocytosis and an elevated count of polymorphonuclear cells, with eosinophilia observed in 10–20% of individuals.
B. henselae and B. quintana can be isolated from blood using lysis-centrifugation blood cultures; however, both species have also been successfully isolated with the BACTEC blood culture method.
Serological assays for B. henselae are being standardized. Numerous commercial testing laboratories do an indirect fluorescence assay. Low positive titers (1:64–1:256) may indicate recent or past infection, whereas titers beyond 1:256 strongly suggest active infection (2).
Subsequent Actions & Unique Considerations
In instances of inconclusive serology, a repeat test after two weeks may aid in confirming a diagnosis.
Imaging
Ultrasound of swollen lymph nodes can assist in assessing other causes of lymphadenopathy, identifying early suppuration of the bubo, and guiding needle aspiration as necessary.
Diagnostic Procedures and Additional Methods
Excisional biopsy or fine needle aspiration is frequently conducted in instances of regional lymphadenopathy.
Pathological Observations
Pathological findings reveal nonspecific granuloma development in the afflicted lymph nodes. A positive Warthin–Starry stain or tissue PCR for Bartonella indicates the possibility of cat-scratch disease, albeit they are not consistently positive.
DIFFERENTIAL DIAGNOSIS • The diagnosis of cat-scratch illness in individuals exhibiting regional lymphadenopathy or a clinical condition characteristic of cat-scratch disease is indicated by the following:
- Interaction with a feline and the existence of a scratch or
main lesion - A confirmed serological assay for Bartonella
– Distinct histopathologic features (the presence of many microabscesses or granulomas in a lymph node biopsy material)
– Exclusion of other recognizable etiologies, particularly mycobacterial infections and suppurative adenitis
INITIAL THERAPY MEDICATION
The literature contains numerous contradicting assertions regarding the role and selection of antibiotics for cat-scratch illness (3).
• While the condition typically resolves spontaneously, antibiotics may expedite recovery and are hence frequently employed in the treatment of cat-scratch disease.
Azithromycin (500 mg orally as a single dose, followed by 250 mg once day for the subsequent four days) is applicable for adults.
The management of cat-scratch neuroretinitis remains contentious; nonetheless, retrospective studies indicate that the combination of doxycycline and rifampin is linked to a more expedited alleviation of symptoms (4).
For bacillary angiomatosis limited to the skin, an oral regimen of erythromycin 500 mg administered four times daily or doxycycline 100 mg taken twice daily for a duration of 8–12 weeks is advised. Lesions typically start to diminish after a week, but generally require a somewhat longer duration to fully resolve and may result in residual hyperpigmentation.
If unresolved by 12 weeks, therapy should be prolonged.
• A minimum of 4 weeks of treatment is required for bacteremia.
Prolonged treatment (2–3 months) is warranted in an HIV-infected patient with chronic or recurrent fever, particularly in the context of endocarditis.
Second Line
Additional oral medications considered useful against cat-scratch disease include rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
• In the event of suppuration, aspiration should be contemplated to alleviate pain and expedite recovery. Needle aspiration is typically favored over incision and drainage. Following the cleansing of the skin with an iodophor skin cleanser, aspiration can be performed by inserting an 18- or 19-gauge needle tangentially through healthy skin near the base of the node. Reaspiration may be required seldom.
In endocarditis, hemodynamic factors may necessitate valve replacement (see to chapters in Section II on endocarditis).
CONTINUING TREATMENT POST-CARE SUGGESTIONS
The lymphadenopathy associated with cat-scratch illness typically recovers spontaneously over several months.
• A single occurrence of cat-scratch sickness seems to provide enduring immunity. Occasionally, a reemergence of sinus tract drainage from the initially affected nodes may transpire. In cases of large adenopathy (>5 cm), chronic adenopathy may endure for 1 to 2 years.
• The resolution of fever in patients with bacteremia often occurs rapidly in non-HIV-infected individuals, however it may extend to several weeks in those infected with HIV. Typically, bacteremia becomes undetectable within a week of initiating medication, despite the potential continuation of fever.
DIET: Standard.
INFORMATION FOR PATIENTS
Patients must be informed about the transmission method and the possible dangers to immunocompromised others in the household who have comparable exposure to cats.
OUTLOOK
Simple cat-scratch illness has a favorable prognosis. Lymphadenopathy related to mild cat-scratch disease in immunocompetent persons heals within weeks to many months. Complications including retinitis, encephalopathy, or severe systemic disease manifest in 5–14% of instances.
COMPLICATIONS
• Encephalopathy typically manifests many weeks following the severe sickness. Seizures and status epilepticus may indicate encephalopathy but are self-limiting, with prompt recovery typically occurring within a few days. The cerebrospinal fluid is typically normal, although pleocytosis may arise. The etiology of the encephalopathy remains ambiguous, while direct infection, a toxin, and an autoimmune mechanism have been suggested as contributing factors.
Inflammatory responses to B. henselae infection in individuals with AIDS, absent of accompanying angiomatosis or peliosis, have been seen affecting the liver and spleen.
lymph nodes, cardiac organ, and bone marrow
CAT-SCRATCH DISEASE (AND BARTONELLA INFECTIONS)
Cat-scratch disease is generally a self-limiting acute condition characterized by regional lymphadenopathy, fever, and systemic symptoms, resulting from Bartonella henselae infection. Other manifestations of B. henselae infection encompass fever of unknown origin, hepatosplenic granulomatous disease, neuroretinitis, and encephalopathy.
Other medically significant Bartonella species comprise: – Bartonella quintana, historically responsible for trench fever, linked with persistent bacteremia, endocarditis, and bacillary angiomatosis. – Bartonella bacilliformis, the etiological agent of Oroya fever.
Epidemiology
Occurrence
The prevalence of cat-scratch disease in the United States is roughly 10 cases per 100,000 person-years, with an estimated 24,000 cases identified annually.
Cat-scratch illness is prevalent globally. In temperate areas, it is seasonal, with the majority of cases occurring from August to January.
Cat-scratch illness manifests in immunocompetent individuals across all age groups, with 80% of cases occurring in those under 21 years old.
Most instances of cat-scratch sickness are self-resolving and linked to regional lymphadenopathy.
B. quintana is considered to be worldwide endemic.
B. bacilliformis infection is transmitted through sand fly bites and is exclusively found at altitudes exceeding 1 km in the Andes mountains.
FACTORS OF RISK
Cats serve as the primary hosts and reservoirs of B. henselae.
Most instances of cat-scratch disease can be directly associated with exposure to cats, particularly kittens or felines infested with fleas. Ninety percent of patients had a history of contact with cats.
- A prior history of cat scratch in 60% of cases.
• Incidences of B. quintana infection have been documented among homeless individuals and those from socioeconomically poor backgrounds. These circumstances render persons susceptible to Pediculus humanus (human body louse), a vector for B. quintana infection.
Patients with advanced HIV infection and other immunocompromised individuals are at elevated risk of
progressive chronic infections induced by B. quintana and B. henselae, encompassing bacillary angiomatosis (vascular lesions) and bacillary peliosis (cystic lesions).
COMPREHENSIVE PREVENTION
The risk of cat-scratch disease can be mitigated by minimizing interactions that could result in scratches, bites, or licks from cats or kittens.
The management of cat fleas may diminish the danger of transmission and may be beneficial in households with immunocompromised individuals.
PATHOPHYSIOLOGY • Bartonella species possess the ability for intracellular persistence and induce inflammation in affected organs.
The inflammatory response in cat-scratch disease leads to localized granuloma development.
ETIOLOGY • Bartonella species are meticulous gram-negative rod-shaped aerobic bacteria. • The predominant cause of cat-scratch disease is B. henselae.
• Additional medically significant Bartonella infections encompass
B. quintana and B. bacilliformis. Numerous additional Bartonella species have been linked to isolated instances of human illness.
FREQUENTLY CO-OCCURRING CONDITIONS
B. henselae and B. quintana induce a unique array of illnesses in HIV infection (see to the preceding section). Chronic infections may also arise in recipients of solid-organ transplants and individuals with hematological malignancies.
HISTORY OF DIAGNOSIS
The primary symptom of cat-scratch disease frequently manifests as a tiny erythematous papule or pustule at the scratch site, which endures for several weeks.
• Consequently, lymph nodes associated with the inoculation site become hypertrophied and sensitive.
Patients with cat-scratch disease may not consistently exhibit fever. Low-grade fever and malaise occur in 30% of patients.
Other indications of cat-scratch disease encompass prolonged fever, neuroretinitis (evidenced by diminished visual acuity or alterations in vision), and encephalopathy (characterized by abnormalities in mental status).
B. henselae bacteremia in individuals infected with HIV is linked to a gradual onset of lethargy, malaise, myalgia, weight loss, recurrent fevers of increasing duration and intensity, and occasionally, headaches. Hepatomegaly may be present.
Trench fever is the quintessential manifestation of B. quintana infection, and its natural progression in healthy individuals has been thoroughly documented. Incubation subsequent to inoculation
may extend from 3 to 38 days before to the typically abrupt emergence of chills and fevers. Afebrile infection represents the least prevalent variant. The accompanying symptoms and signs (e.g., headache, vertigo, retro-orbital pain, conjunctival infection) are all vague.
The physical morphology of bacillary angiomatosis is characterized by subcutaneous or dermal nodules and/or single or numerous dome-shaped papules that are skin-colored or red-to-purple, which may exhibit ulceration, serous or bloody exudate, and crusting. Visceral lesions can be notably striking, both in their quantity and the diversity of their macroscopic appearance.
Bacillary peliosis affects organs characterized by multiple blood-filled cystic formations, varying in size from microscopic to several millimeters.
PHYSICAL EXAM • Regional lymphadenopathy is the predominant physical manifestation in cat-scratch disease, occurring in lymph nodes that drain the inoculation site. • In numerous instances, a tiny granuloma or lesion may be identified at the site of inoculation.
Parinaud’s oculoglandular syndrome occurs in roughly 5% of individuals with cat-scratch disease, characterized by conjunctivitis, conjunctival granuloma, and preauricular lymphadenopathy.
Patients with visceral disease may exhibit hepatosplenomegaly.
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Initial Assessments
In the initial stages of the disease, the total white blood cell count may reveal mild leukocytosis and an elevated count of polymorphonuclear cells, with eosinophilia observed in 10–20% of individuals.
B. henselae and B. quintana can be isolated from blood using lysis-centrifugation blood cultures; however, both species have also been successfully isolated with the BACTEC blood culture method.
Serological assays for B. henselae are being standardized. Numerous commercial testing laboratories do an indirect fluorescence assay. Low positive titers (1:64–1:256) may indicate recent or past infection, whereas titers beyond 1:256 strongly suggest active infection (2).
Subsequent Actions & Unique Considerations
In instances of inconclusive serology, a repeat test after two weeks may aid in confirming a diagnosis.
Imaging
Ultrasound of swollen lymph nodes can assist in assessing other causes of lymphadenopathy, identifying early suppuration of the bubo, and guiding needle aspiration as necessary.
Diagnostic Procedures and Additional Methods
Excisional biopsy or fine needle aspiration is frequently conducted in instances of regional lymphadenopathy.
Pathological Observations
Pathological findings reveal nonspecific granuloma development in the afflicted lymph nodes. A positive Warthin–Starry stain or tissue PCR for Bartonella indicates the possibility of cat-scratch disease, albeit they are not consistently positive.
DIFFERENTIAL DIAGNOSIS • The diagnosis of cat-scratch illness in individuals exhibiting regional lymphadenopathy or a clinical condition characteristic of cat-scratch disease is indicated by the following:
- Interaction with a feline and the existence of a scratch or
main lesion - A confirmed serological assay for Bartonella
– Distinct histopathologic features (the presence of many microabscesses or granulomas in a lymph node biopsy material)
– Exclusion of other recognizable etiologies, particularly mycobacterial infections and suppurative adenitis
INITIAL THERAPY MEDICATION
The literature contains numerous contradicting assertions regarding the role and selection of antibiotics for cat-scratch illness (3).
• While the condition typically resolves spontaneously, antibiotics may expedite recovery and are hence frequently employed in the treatment of cat-scratch disease.
Azithromycin (500 mg orally as a single dose, followed by 250 mg once day for the subsequent four days) is applicable for adults.
The management of cat-scratch neuroretinitis remains contentious; nonetheless, retrospective studies indicate that the combination of doxycycline and rifampin is linked to a more expedited alleviation of symptoms (4).
For bacillary angiomatosis limited to the skin, an oral regimen of erythromycin 500 mg administered four times daily or doxycycline 100 mg taken twice daily for a duration of 8–12 weeks is advised. Lesions typically start to diminish after a week, but generally require a somewhat longer duration to fully resolve and may result in residual hyperpigmentation.
If unresolved by 12 weeks, therapy should be prolonged.
• A minimum of 4 weeks of treatment is required for bacteremia.
Prolonged treatment (2–3 months) is warranted in an HIV-infected patient with chronic or recurrent fever, particularly in the context of endocarditis.
Second Line
Additional oral medications considered useful against cat-scratch disease include rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
• In the event of suppuration, aspiration should be contemplated to alleviate pain and expedite recovery. Needle aspiration is typically favored over incision and drainage. Following the cleansing of the skin with an iodophor skin cleanser, aspiration can be performed by inserting an 18- or 19-gauge needle tangentially through healthy skin near the base of the node. Reaspiration may be required seldom.
In endocarditis, hemodynamic factors may necessitate valve replacement (see to chapters in Section II on endocarditis).
CONTINUING TREATMENT POST-CARE SUGGESTIONS
The lymphadenopathy associated with cat-scratch illness typically recovers spontaneously over several months.
• A single occurrence of cat-scratch sickness seems to provide enduring immunity. Occasionally, a reemergence of sinus tract drainage from the initially affected nodes may transpire. In cases of large adenopathy (>5 cm), chronic adenopathy may endure for 1 to 2 years.
• The resolution of fever in patients with bacteremia often occurs rapidly in non-HIV-infected individuals, however it may extend to several weeks in those infected with HIV. Typically, bacteremia becomes undetectable within a week of initiating medication, despite the potential continuation of fever.
DIET: Standard.
INFORMATION FOR PATIENTS
Patients must be informed about the transmission method and the possible dangers to immunocompromised others in the household who have comparable exposure to cats.
OUTLOOK
Simple cat-scratch illness has a favorable prognosis. Lymphadenopathy related to mild cat-scratch disease in immunocompetent persons heals within weeks to many months. Complications including retinitis, encephalopathy, or severe systemic disease manifest in 5–14% of instances.
COMPLICATIONS
• Encephalopathy typically manifests many weeks following the severe sickness. Seizures and status epilepticus may indicate encephalopathy but are self-limiting, with prompt recovery typically occurring within a few days. The cerebrospinal fluid is typically normal, although pleocytosis may arise. The etiology of the encephalopathy remains ambiguous, while direct infection, a toxin, and an autoimmune mechanism have been suggested as contributing factors.
Inflammatory responses to B. henselae infection in individuals with AIDS, absent of accompanying angiomatosis or peliosis, have been seen affecting the liver and spleen.
lymph nodes, cardiac organ, and bone marrow
- Published on
Infectious Disease - Candidiasis
CANDIDIASIS
DESCRIPTION • Candida is a yeast that constitutes part of the normal flora on the skin and within the gastrointestinal and genitourinary tracts. • Candida species are an emerging cause of bloodstream infections in immunocompromised individuals. • Candida can induce both superficial and systemic infections.
Epidemiology: Candidal infections can affect individuals of all ages; however, they are more prevalent among the elderly, babies, and pregnant women.
• A recent study revealed that up to 9% of bloodstream infections in US hospitals were associated with candidal infection.
– Numerous varieties of Candida exist, with Candida albicans being the primary organism associated with the majority of illnesses. Non-albicans Candida species are rising in prevalence. In a recent specimen
Among over 1400 Candida specimens from hospitalized patients, the most prevalent species following C. albicans were C. parapsilosis, C. glabrata, and C. tropicalis.
RISK FACTORS • Immune suppression/neutropenia (2) • Preexisting conditions associated with immune suppression, including cancer, AIDS, and significant burns
• Extended antibiotic administration • Indwelling intravenous catheter • Chemotherapeutic treatment • Recipients of solid organ and bone marrow transplants • Total parenteral nutrition • Chronic renal insufficiency and hemodialysis • Gastrointestinal perforation • Diabetes mellitus • Gestation • Glucocorticoid therapy
GENERAL PREVENTION
• Prudent use of antibiotics. • Extraction of central venous catheters when no longer required.
PATHOPHYSIOLOGY
• Candidemia may arise from disruptions in mucosal barriers at any location within the gastrointestinal system. • Candidemia may also result from the colonization of intravascular catheter devices.
ETIOLOGY • The genus Candida has over 150 species, with the clinically significant species being C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, and C. lusitaniae. • C. albicans is responsible for over 50% of candidemia cases.
FREQUENTLY CO-OCCURRING CONDITIONS
Immunosuppression due to chemotherapy, HIV/AIDS, solid organ or bone marrow transplantation, neutropenia, or severe underlying conditions necessitating extended ICU admissions with intravenous catheters.
DIAGNOSTIC HISTORY
The clinical presentation and assessment of risk factors are contingent upon the affected organ (e.g., genitourinary and intestinal tracts, brain, skin) and the severity of the disease.
• Vulvovaginal candidiasis: Itching, discomfort, painful urination, painful intercourse, and white, curd-like discharge.
• Oropharyngeal candidiasis: Intermittent discomfort, taste impairment, occasionally asymptomatic.
• Candida esophagitis: Nausea, vomiting, retrosternal chest discomfort, odynophagia, dysphagia.
• Invasive candidiasis: History of immunosuppressive therapy, HIV/AIDS, concomitant malignancy. Mental status alterations may occur if sepsis.
PHYSICAL EXAMINATION
• It is contingent upon the affected organ and the severity of the condition.
• Vulvovaginal candidiasis: Erythema of the vulva or vagina accompanied by a white, curd-like discharge. Occasionally, there is a transparent discharge.
• Oral candidiasis (thrush) and Candida esophagitis: Presence of white plaques on the tongue, hard palate, and soft palate. Frequently results in an erythematous base upon removal. Patients may exhibit esophageal candidiasis in the absence of oral involvement.
Candidemia presents with symptoms ranging from fever to indications of severe sepsis, including hypotension, tachycardia, and alterations in mental status.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Vulvovaginal candidiasis: Often a clinical diagnosis. The pH of vaginal discharge may vary between 4 and 4.5. Yeast will be observed in microscopic examinations of KOH preparations or wet mounts (3,4).
• Oral candidiasis (thrush): Frequently diagnosed clinically as well. Confirmation can be achieved by examining scrapings on KOH preparations using light microscopy.
Esophageal candidiasis may necessitate endoscopy and biopsy for diagnosis.
Candidemia: Gram staining or proliferation in blood cultures. Candida must not be regarded as a blood contamination.
Susceptibility testing for fluconazole should be conducted in cases of severe infection or in affected people.
ineffective against first-line treatments.
Imaging: Preliminary Strategy
• Neurological assessment: CT scan and MRI of the brain.
• Endocarditis: Transesophageal echocardiography • Esophagitis: Upper endoscopy with biopsy
• Spleen and liver: MRI surpasses CT
Pneumonia: Chest X-ray, Computed Tomography
• Peritonitis: Fluid aspiration guided by CT or ultrasound
Subsequent Actions & Specific Considerations
• For candidemia: Provide general ICU care for stabilization, as death rates may exceed 30–40%.
5–10% of candidemia cases are associated with endophthalmitis complications. Ophthalmology must be consulted in every instance of candidemia.
Diagnostic Procedures/Additional Candida esophagitis: While endoscopy and biopsy represent the definitive method for identifying Candida esophagitis, numerous individuals receive empirical treatment when they exhibit significant symptoms alongside risk factors and oral manifestations.
Candidiasis. It is important to note that oral candidiasis is not a prerequisite for esophageal candidal infections.
Pathological Observations
Yeast exhibiting and lacking pseudohyphae
DIFFERENTIAL DIAGNOSIS
• Oral hairy leukoplakia • Contact dermatitis • Atrophic vaginitis • Bacterial sepsis • Endocarditis • Fever of unknown origin • Cytomegalovirus (CMV) esophagitis
INITIAL THERAPEUTIC AGENT
• Vulvovaginal candidiasis: Various topical treatments are accessible, such as butoconazole cream 5 g/day for 3 days. Oral alternatives are also accessible, including fluconazole 150 mg administered orally as a single dose. Prolonged treatment duration is necessary in severe cases or immunocompromised individuals. Administration of butoconazole cream for 5 to 7 days, or oral fluconazole for up to 7 days, may be required (5–7).
• Oral candidiasis (thrush): Nystatin oral solution (suspension), clotrimazole oral troche, or fluconazole 100–200 mg/day. The therapeutic duration typically spans 5 days following the resolution of symptoms.
Candida esophagitis: Administer Fluconazole 400 mg as a first dose, followed by 200–400 mg daily for a duration of 7–14 days. This can be administered orally, but may be delivered intravenously in certain patients with pronounced dysphagia or odynophagia.
• Candidemia: The selection of empirical therapy is contingent upon the
Candida should undergo culture and sensitivity testing for triazoles (e.g., fluconazole) (8,9). In stable, non-neutropenic patients devoid of antifungal exposure, fluconazole (800 mg intravenously once, followed by 400 mg intravenously daily) is a judicious option. All other patients, including those who are unstable, neutropenic, have prior antifungal exposure, or have experienced recent or extended hospitalizations, should receive empirical treatment with either an echinocandin (caspofungin, micafungin, or anidulafungin), voriconazole, or lipid formulations of amphotericin B. This may be modified to fluconazole if the sample exhibits sensitivity.
C. krusei exhibits resistance to fluconazole.
C. glabrata frequently exhibits resistance to triazoles.
C. parapsilosis isolates have elevated minimum inhibitory concentrations (MICs) to echinocandins.
C. lusitaniae exhibits resistance to amphotericin B. The advised length of antifungal treatment is a minimum of 2 weeks following the negative results of blood cultures. Verify the implementation of adequate "source control" (e.g., intravenous lines have been removed and substituted).
Esophageal candidiasis: In instances of fluconazole resistance, alternative triazoles, including itraconazole, posaconazole, and voriconazole, shown efficacy. An echinocandin, such as caspofungin, micafungin, or anidulafungin, may be utilized in
Patients who are hospitalized can only receive it in intravenous form.
SUPPLEMENTARY THERAPY
Concerns for Referral
Infectious disease specialists should be sought for bloodstream Candida infections and for guidance in managing neutropenic patients.
Pharmacists are invaluable due to the numerous drug interactions associated with antifungal drugs, particularly the triazoles. Exercise caution when concurrently administering warfarin, rifampin, antiepileptic drugs, and sulfonylureas.
OPERATIONS/ADDITIONAL INTERVENTIONS
A surgical consultation is necessary to drain fluid collections infected with Candida species and to manage candidal endocarditis.
INPATIENT CONSIDERATIONS
Criteria for Admission
Patients suspected with candidemia should be hospitalized and administered empiric antifungal medication.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
Patient Surveillance
QT prolongation must be monitored via ECGs in patients administered triazoles (e.g., fluconazole, voriconazole).
• The pharmacy must evaluate potential drug interactions while administering antifungal medicines, particularly triazoles.
• Conduct daily blood cultures in patients with candidemia to confirm sterilization.
• Ophthalmology should evaluate all patients with candidemia for endophthalmitis.
OUTLOOK
Mortality progressively rises in patients with candidemia who have a delay in antifungal treatment. For instance, individuals treated three or more days after confirmed candidemia exhibit mortality rates above 40%.
COMPLICATIONS • Renal failure • Esophageal perforation • Endocarditis • Endophthalmitis • Meningitis • Peritonitis and adhesions • Pericarditis • Abscess • Mortality
CANDIDIASIS
DESCRIPTION • Candida is a yeast that constitutes part of the normal flora on the skin and within the gastrointestinal and genitourinary tracts. • Candida species are an emerging cause of bloodstream infections in immunocompromised individuals. • Candida can induce both superficial and systemic infections.
Epidemiology: Candidal infections can affect individuals of all ages; however, they are more prevalent among the elderly, babies, and pregnant women.
• A recent study revealed that up to 9% of bloodstream infections in US hospitals were associated with candidal infection.
– Numerous varieties of Candida exist, with Candida albicans being the primary organism associated with the majority of illnesses. Non-albicans Candida species are rising in prevalence. In a recent specimen
Among over 1400 Candida specimens from hospitalized patients, the most prevalent species following C. albicans were C. parapsilosis, C. glabrata, and C. tropicalis.
RISK FACTORS • Immune suppression/neutropenia (2) • Preexisting conditions associated with immune suppression, including cancer, AIDS, and significant burns
• Extended antibiotic administration • Indwelling intravenous catheter • Chemotherapeutic treatment • Recipients of solid organ and bone marrow transplants • Total parenteral nutrition • Chronic renal insufficiency and hemodialysis • Gastrointestinal perforation • Diabetes mellitus • Gestation • Glucocorticoid therapy
GENERAL PREVENTION
• Prudent use of antibiotics. • Extraction of central venous catheters when no longer required.
PATHOPHYSIOLOGY
• Candidemia may arise from disruptions in mucosal barriers at any location within the gastrointestinal system. • Candidemia may also result from the colonization of intravascular catheter devices.
ETIOLOGY • The genus Candida has over 150 species, with the clinically significant species being C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, and C. lusitaniae. • C. albicans is responsible for over 50% of candidemia cases.
FREQUENTLY CO-OCCURRING CONDITIONS
Immunosuppression due to chemotherapy, HIV/AIDS, solid organ or bone marrow transplantation, neutropenia, or severe underlying conditions necessitating extended ICU admissions with intravenous catheters.
DIAGNOSTIC HISTORY
The clinical presentation and assessment of risk factors are contingent upon the affected organ (e.g., genitourinary and intestinal tracts, brain, skin) and the severity of the disease.
• Vulvovaginal candidiasis: Itching, discomfort, painful urination, painful intercourse, and white, curd-like discharge.
• Oropharyngeal candidiasis: Intermittent discomfort, taste impairment, occasionally asymptomatic.
• Candida esophagitis: Nausea, vomiting, retrosternal chest discomfort, odynophagia, dysphagia.
• Invasive candidiasis: History of immunosuppressive therapy, HIV/AIDS, concomitant malignancy. Mental status alterations may occur if sepsis.
PHYSICAL EXAMINATION
• It is contingent upon the affected organ and the severity of the condition.
• Vulvovaginal candidiasis: Erythema of the vulva or vagina accompanied by a white, curd-like discharge. Occasionally, there is a transparent discharge.
• Oral candidiasis (thrush) and Candida esophagitis: Presence of white plaques on the tongue, hard palate, and soft palate. Frequently results in an erythematous base upon removal. Patients may exhibit esophageal candidiasis in the absence of oral involvement.
Candidemia presents with symptoms ranging from fever to indications of severe sepsis, including hypotension, tachycardia, and alterations in mental status.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Vulvovaginal candidiasis: Often a clinical diagnosis. The pH of vaginal discharge may vary between 4 and 4.5. Yeast will be observed in microscopic examinations of KOH preparations or wet mounts (3,4).
• Oral candidiasis (thrush): Frequently diagnosed clinically as well. Confirmation can be achieved by examining scrapings on KOH preparations using light microscopy.
Esophageal candidiasis may necessitate endoscopy and biopsy for diagnosis.
Candidemia: Gram staining or proliferation in blood cultures. Candida must not be regarded as a blood contamination.
Susceptibility testing for fluconazole should be conducted in cases of severe infection or in affected people.
ineffective against first-line treatments.
Imaging: Preliminary Strategy
• Neurological assessment: CT scan and MRI of the brain.
• Endocarditis: Transesophageal echocardiography • Esophagitis: Upper endoscopy with biopsy
• Spleen and liver: MRI surpasses CT
Pneumonia: Chest X-ray, Computed Tomography
• Peritonitis: Fluid aspiration guided by CT or ultrasound
Subsequent Actions & Specific Considerations
• For candidemia: Provide general ICU care for stabilization, as death rates may exceed 30–40%.
5–10% of candidemia cases are associated with endophthalmitis complications. Ophthalmology must be consulted in every instance of candidemia.
Diagnostic Procedures/Additional Candida esophagitis: While endoscopy and biopsy represent the definitive method for identifying Candida esophagitis, numerous individuals receive empirical treatment when they exhibit significant symptoms alongside risk factors and oral manifestations.
Candidiasis. It is important to note that oral candidiasis is not a prerequisite for esophageal candidal infections.
Pathological Observations
Yeast exhibiting and lacking pseudohyphae
DIFFERENTIAL DIAGNOSIS
• Oral hairy leukoplakia • Contact dermatitis • Atrophic vaginitis • Bacterial sepsis • Endocarditis • Fever of unknown origin • Cytomegalovirus (CMV) esophagitis
INITIAL THERAPEUTIC AGENT
• Vulvovaginal candidiasis: Various topical treatments are accessible, such as butoconazole cream 5 g/day for 3 days. Oral alternatives are also accessible, including fluconazole 150 mg administered orally as a single dose. Prolonged treatment duration is necessary in severe cases or immunocompromised individuals. Administration of butoconazole cream for 5 to 7 days, or oral fluconazole for up to 7 days, may be required (5–7).
• Oral candidiasis (thrush): Nystatin oral solution (suspension), clotrimazole oral troche, or fluconazole 100–200 mg/day. The therapeutic duration typically spans 5 days following the resolution of symptoms.
Candida esophagitis: Administer Fluconazole 400 mg as a first dose, followed by 200–400 mg daily for a duration of 7–14 days. This can be administered orally, but may be delivered intravenously in certain patients with pronounced dysphagia or odynophagia.
• Candidemia: The selection of empirical therapy is contingent upon the
Candida should undergo culture and sensitivity testing for triazoles (e.g., fluconazole) (8,9). In stable, non-neutropenic patients devoid of antifungal exposure, fluconazole (800 mg intravenously once, followed by 400 mg intravenously daily) is a judicious option. All other patients, including those who are unstable, neutropenic, have prior antifungal exposure, or have experienced recent or extended hospitalizations, should receive empirical treatment with either an echinocandin (caspofungin, micafungin, or anidulafungin), voriconazole, or lipid formulations of amphotericin B. This may be modified to fluconazole if the sample exhibits sensitivity.
C. krusei exhibits resistance to fluconazole.
C. glabrata frequently exhibits resistance to triazoles.
C. parapsilosis isolates have elevated minimum inhibitory concentrations (MICs) to echinocandins.
C. lusitaniae exhibits resistance to amphotericin B. The advised length of antifungal treatment is a minimum of 2 weeks following the negative results of blood cultures. Verify the implementation of adequate "source control" (e.g., intravenous lines have been removed and substituted).
Esophageal candidiasis: In instances of fluconazole resistance, alternative triazoles, including itraconazole, posaconazole, and voriconazole, shown efficacy. An echinocandin, such as caspofungin, micafungin, or anidulafungin, may be utilized in
Patients who are hospitalized can only receive it in intravenous form.
SUPPLEMENTARY THERAPY
Concerns for Referral
Infectious disease specialists should be sought for bloodstream Candida infections and for guidance in managing neutropenic patients.
Pharmacists are invaluable due to the numerous drug interactions associated with antifungal drugs, particularly the triazoles. Exercise caution when concurrently administering warfarin, rifampin, antiepileptic drugs, and sulfonylureas.
OPERATIONS/ADDITIONAL INTERVENTIONS
A surgical consultation is necessary to drain fluid collections infected with Candida species and to manage candidal endocarditis.
INPATIENT CONSIDERATIONS
Criteria for Admission
Patients suspected with candidemia should be hospitalized and administered empiric antifungal medication.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
Patient Surveillance
QT prolongation must be monitored via ECGs in patients administered triazoles (e.g., fluconazole, voriconazole).
• The pharmacy must evaluate potential drug interactions while administering antifungal medicines, particularly triazoles.
• Conduct daily blood cultures in patients with candidemia to confirm sterilization.
• Ophthalmology should evaluate all patients with candidemia for endophthalmitis.
OUTLOOK
Mortality progressively rises in patients with candidemia who have a delay in antifungal treatment. For instance, individuals treated three or more days after confirmed candidemia exhibit mortality rates above 40%.
COMPLICATIONS • Renal failure • Esophageal perforation • Endocarditis • Endophthalmitis • Meningitis • Peritonitis and adhesions • Pericarditis • Abscess • Mortality
- Published on
Infectious Disease – Campylobacter Infections
CAMPYLOBACTER INFECTIONS
BASIC DESCRIPTION
• Campylobacter species are a significant foodborne etiological agent of diarrheal diseases in both developed and developing nations. • Postinfectious sequelae of Campylobacter infection encompass Guillain–Barré syndrome and reactive arthritis.
EPIDEMIOLOGY
Incidence
Campylobacteriosis is a global zoonotic disease, and Campylobacter enteritis is a prevalent kind of acute gastroenteritis in North America.
C. jejuni infections manifest throughout the year in the United States and other industrialized nations, with a pronounced surge during the summer and early autumn months.
• As much as 90% of broiler birds exhibit contamination.
Campylobacter bacteria are readily transmitted by contaminated drinking water and unpasteurized milk. Certain instances are linked to the preparation of contaminated food. However, the epidemiology of the infection in poor nations differs, as C. jejuni is frequently isolated from asymptomatic individuals and is particularly prevalent during the initial five years of life.
RISK FACTORS
In wealthy nations, the intake of undercooked poultry is believed to account for over fifty percent of sporadic Campylobacter infection cases.
HIV-positive individuals exhibit an elevated susceptibility to infections.
Genetics
Reactive arthritis may manifest several weeks after infection in individuals possessing HLA-B27 histocompatibility antigens.
GENERAL PREVENTION • Campylobacter can be eradicated by roasting poultry and other meats to an internal temperature of 82°C (180°F). The temperature at which the meat ceases to exhibit a pink hue and the juices flow clear is specified. Poultry and other meats must be prepared separately from other items, both in commercial establishments and domestic settings.
Countertops, utensils, towels, and aprons utilized in the preparation of chicken and other meats must be cleansed with hot water and soap prior to being employed for other items, especially those that will not undergo cooking.
Handwashing is crucial.
Suspected cases, especially those linked to additional instances within family or acquaintances, must be reported immediately to the local health authority.
Pathophysiology
The incubation period varies from 1 to 7 days.
• A mere 500 germs can induce sickness in certain persons.
The proven correlation between Campylobacter infection and Guillain–Barré syndrome is believed to stem from molecular mimicry, due to the structural similarity of antigens shared by Campylobacter and peripheral nerves.
ETIOLOGY • Campylobacter jejuni and Campylobacter coli are the primary etiological agents of Campylobacter infection in humans.
C. fetus is a significant etiological agent of systemic infection and chronic bacteremia in immunocompromised individuals.
However, it is not a significant cause of enteritis in immunocompetent individuals.
HISTORY OF DIAGNOSIS
• Acute enteritis is the predominant manifestation of C. jejuni infection. • Symptoms may persist for a duration ranging from 1 day to over 1 week.
• Frequently, a prodrome presents with fever, headache, myalgia, and malaise.
• The predominant symptoms are as follows:
- Abdominal discomfort (often cramping) – Diarrhea – Fever (often low-grade but may reach 40°C or higher)
Malaise
• Diarrhea can range from loose stools to profuse watery stools or visibly bloody stools.
• Infections caused by C. fetal might result in intermittent diarrhea or general abdominal discomfort without localized symptoms. • C. fetus may also lead to a lengthy relapsing illness marked by fever, chills, and myalgia, with no identifiable source of infection.
PHYSICAL EXAMINATION
• Physical examination results in the majority of Campylobacter enteritis cases are nonspecific, typically revealing minor abdominal pain.
• In few instances, intense stomach discomfort may cause Campylobacter enteritis to resemble appendicitis (pseudoappendicitis); nevertheless, typical physical indications of peritonitis, such as guarding and rebound soreness, are infrequent.
DIAGNOSTIC TESTS AND INTERPRETATION Lab
In numerous instances of Campylobacter enteritis, a modest leukocytosis accompanied by an elevation in neutrophils is observed.
The diagnosis of Campylobacter jejuni infection is often established through a positive stool culture.
• Campylobacter species are extracted from fecal samples utilizing microaerobic incubation conditions and selective methods that inhibit the proliferation of competing microorganisms. • Bacteremia occurs in less than 1% of individuals with C. jejuni infection.
DIFFERENTIAL DIAGNOSIS
The diagnosis may be inferred from the symptoms.
This can be readily verified using stool culture.
INITIAL THERAPEUTIC AGENT
• Antimicrobial therapy is warranted for individuals with severe or prolonged symptoms, or those with risk factors for consequences, including pregnancy, immunocompromising diseases, or advanced age, as most infections are self-limiting.
Ciprofloxacin (500 mg orally, twice day for 5–7 days) is regarded as a first-line treatment. Nonetheless, the resistance of Campylobacter to quinolones is escalating.
Macrolides, such as erythromycin, represent an additional suitable first-line therapy. The advised dosage for adults is 250 mg orally four times daily for 5–7 days; for children, the suggested dosage is 30–50 mg/kg per day in divided doses for the same duration.
Campylobacter strains obtained in underdeveloped nations exhibit a higher propensity for erythromycin resistance.
The requirement for addressing septic or bacteremic episodes with drugs other than ciprofloxacin has not been determined. For patients with severe toxicity-
Prolonged treatment with gentamicin or imipenem is warranted.
Second Line
Most isolates of C. jejuni and C. coli exhibit resistance to cephalosporins and penicillin; hence, these drugs should be avoided.
• The susceptibility to sulfonamides and metronidazole is inconsistent. Treatment with antimicrobial drugs does not extend the carriage of C. jejuni, unlike Salmonella infections; rather, it typically eradicates carriage within 72 hours in the majority of patients.
SUPPLEMENTARY THERAPY
Comprehensive Strategies
Evaluation of hydration status and suitable fluid and electrolyte replenishment are necessary.
Supplementary Treatments
• The administration of an antimotility agent may extend the duration of symptoms unless it is administered together with an antibiotic. • Antimotility treatments are contraindicated in pediatric patients.
INPATIENT CONSIDERATIONS
Admission Criteria • A limited number of patients with Campylobacter enteritis necessitate hospitalization. • Possible reasons for admission encompass moderate to severe dehydration, intense pain, systemic sickness, or complications (elaborated below).
Intravenous Fluids
Only isotonic solutions should be administered to individuals experiencing severe dehydration.
CONTINUING CARE POST-TREATMENT RECOMMENDATIONS
Postinfectious consequences of Campylobacter enteritis typically manifest within two months following the acute infection.
Patient Surveillance
Patients experiencing recurrent diarrhea should be closely watched through meticulous documentation of fluid intake and output, as well as for indications of dehydration.
DIET
Patients with enteritis may maintain a regular diet as tolerated.
PROGNOSIS
• The majority of patients achieve complete recovery from Campylobacter enteritis, either spontaneously or with suitable antimicrobial treatment.
• Campylobacter infections are the most prevalent.
While Campylobacter enteritis is a well acknowledged antecedent of Guillain–Barré syndrome, it is crucial to note that only 1 in every 1000 people with this condition eventually develops GBS, indicating a minimal risk for any individual.
• Infection with C. fetus may be fatal for individuals with chronic compensated conditions such as cirrhosis or diabetes mellitus.
consequences • The primary postinfectious consequences of Campylobacter enteritis in immunocompetent individuals are reactive arthritis and Guillain–Barré syndrome, as previously mentioned.
• • • • •
Campylobacter infections can be fatal in immunocompromised persons.
Campylobacter jejuni may induce septic abortion.
Reports of C. jejuni infections presenting with acute cholecystitis, pancreatitis, and cystitis have been sporadic.
Campylobacter jejuni has been linked to an intestinal immunoproliferative disease characterized by malabsorption and protein-losing enteropathy.
C. fetal infections demonstrate a preference for arterial locations; vascular necrosis is observed in patients with endocarditis and pericarditis.
CNS infections caused by C. fetus manifest in neonates and
individuals of mature age. The prognosis for premature infants is unfavorable; nonetheless, certain full-term neonates have survived infections. The infection presents as meningoencephalitis characterized by polymorphonuclear pleocytosis in the cerebrospinal fluid.
In immunocompromised patients, particularly those with AIDS, bacteremia caused by the "atypical" Campylobacter species occurs rather frequently and may persist indefinitely in the absence of antibiotic treatment.
CAMPYLOBACTER INFECTIONS
BASIC DESCRIPTION
• Campylobacter species are a significant foodborne etiological agent of diarrheal diseases in both developed and developing nations. • Postinfectious sequelae of Campylobacter infection encompass Guillain–Barré syndrome and reactive arthritis.
EPIDEMIOLOGY
Incidence
Campylobacteriosis is a global zoonotic disease, and Campylobacter enteritis is a prevalent kind of acute gastroenteritis in North America.
C. jejuni infections manifest throughout the year in the United States and other industrialized nations, with a pronounced surge during the summer and early autumn months.
• As much as 90% of broiler birds exhibit contamination.
Campylobacter bacteria are readily transmitted by contaminated drinking water and unpasteurized milk. Certain instances are linked to the preparation of contaminated food. However, the epidemiology of the infection in poor nations differs, as C. jejuni is frequently isolated from asymptomatic individuals and is particularly prevalent during the initial five years of life.
RISK FACTORS
In wealthy nations, the intake of undercooked poultry is believed to account for over fifty percent of sporadic Campylobacter infection cases.
HIV-positive individuals exhibit an elevated susceptibility to infections.
Genetics
Reactive arthritis may manifest several weeks after infection in individuals possessing HLA-B27 histocompatibility antigens.
GENERAL PREVENTION • Campylobacter can be eradicated by roasting poultry and other meats to an internal temperature of 82°C (180°F). The temperature at which the meat ceases to exhibit a pink hue and the juices flow clear is specified. Poultry and other meats must be prepared separately from other items, both in commercial establishments and domestic settings.
Countertops, utensils, towels, and aprons utilized in the preparation of chicken and other meats must be cleansed with hot water and soap prior to being employed for other items, especially those that will not undergo cooking.
Handwashing is crucial.
Suspected cases, especially those linked to additional instances within family or acquaintances, must be reported immediately to the local health authority.
Pathophysiology
The incubation period varies from 1 to 7 days.
• A mere 500 germs can induce sickness in certain persons.
The proven correlation between Campylobacter infection and Guillain–Barré syndrome is believed to stem from molecular mimicry, due to the structural similarity of antigens shared by Campylobacter and peripheral nerves.
ETIOLOGY • Campylobacter jejuni and Campylobacter coli are the primary etiological agents of Campylobacter infection in humans.
C. fetus is a significant etiological agent of systemic infection and chronic bacteremia in immunocompromised individuals.
However, it is not a significant cause of enteritis in immunocompetent individuals.
HISTORY OF DIAGNOSIS
• Acute enteritis is the predominant manifestation of C. jejuni infection. • Symptoms may persist for a duration ranging from 1 day to over 1 week.
• Frequently, a prodrome presents with fever, headache, myalgia, and malaise.
• The predominant symptoms are as follows:
- Abdominal discomfort (often cramping) – Diarrhea – Fever (often low-grade but may reach 40°C or higher)
Malaise
• Diarrhea can range from loose stools to profuse watery stools or visibly bloody stools.
• Infections caused by C. fetal might result in intermittent diarrhea or general abdominal discomfort without localized symptoms. • C. fetus may also lead to a lengthy relapsing illness marked by fever, chills, and myalgia, with no identifiable source of infection.
PHYSICAL EXAMINATION
• Physical examination results in the majority of Campylobacter enteritis cases are nonspecific, typically revealing minor abdominal pain.
• In few instances, intense stomach discomfort may cause Campylobacter enteritis to resemble appendicitis (pseudoappendicitis); nevertheless, typical physical indications of peritonitis, such as guarding and rebound soreness, are infrequent.
DIAGNOSTIC TESTS AND INTERPRETATION Lab
In numerous instances of Campylobacter enteritis, a modest leukocytosis accompanied by an elevation in neutrophils is observed.
The diagnosis of Campylobacter jejuni infection is often established through a positive stool culture.
• Campylobacter species are extracted from fecal samples utilizing microaerobic incubation conditions and selective methods that inhibit the proliferation of competing microorganisms. • Bacteremia occurs in less than 1% of individuals with C. jejuni infection.
DIFFERENTIAL DIAGNOSIS
The diagnosis may be inferred from the symptoms.
This can be readily verified using stool culture.
INITIAL THERAPEUTIC AGENT
• Antimicrobial therapy is warranted for individuals with severe or prolonged symptoms, or those with risk factors for consequences, including pregnancy, immunocompromising diseases, or advanced age, as most infections are self-limiting.
Ciprofloxacin (500 mg orally, twice day for 5–7 days) is regarded as a first-line treatment. Nonetheless, the resistance of Campylobacter to quinolones is escalating.
Macrolides, such as erythromycin, represent an additional suitable first-line therapy. The advised dosage for adults is 250 mg orally four times daily for 5–7 days; for children, the suggested dosage is 30–50 mg/kg per day in divided doses for the same duration.
Campylobacter strains obtained in underdeveloped nations exhibit a higher propensity for erythromycin resistance.
The requirement for addressing septic or bacteremic episodes with drugs other than ciprofloxacin has not been determined. For patients with severe toxicity-
Prolonged treatment with gentamicin or imipenem is warranted.
Second Line
Most isolates of C. jejuni and C. coli exhibit resistance to cephalosporins and penicillin; hence, these drugs should be avoided.
• The susceptibility to sulfonamides and metronidazole is inconsistent. Treatment with antimicrobial drugs does not extend the carriage of C. jejuni, unlike Salmonella infections; rather, it typically eradicates carriage within 72 hours in the majority of patients.
SUPPLEMENTARY THERAPY
Comprehensive Strategies
Evaluation of hydration status and suitable fluid and electrolyte replenishment are necessary.
Supplementary Treatments
• The administration of an antimotility agent may extend the duration of symptoms unless it is administered together with an antibiotic. • Antimotility treatments are contraindicated in pediatric patients.
INPATIENT CONSIDERATIONS
Admission Criteria • A limited number of patients with Campylobacter enteritis necessitate hospitalization. • Possible reasons for admission encompass moderate to severe dehydration, intense pain, systemic sickness, or complications (elaborated below).
Intravenous Fluids
Only isotonic solutions should be administered to individuals experiencing severe dehydration.
CONTINUING CARE POST-TREATMENT RECOMMENDATIONS
Postinfectious consequences of Campylobacter enteritis typically manifest within two months following the acute infection.
Patient Surveillance
Patients experiencing recurrent diarrhea should be closely watched through meticulous documentation of fluid intake and output, as well as for indications of dehydration.
DIET
Patients with enteritis may maintain a regular diet as tolerated.
PROGNOSIS
• The majority of patients achieve complete recovery from Campylobacter enteritis, either spontaneously or with suitable antimicrobial treatment.
• Campylobacter infections are the most prevalent.
While Campylobacter enteritis is a well acknowledged antecedent of Guillain–Barré syndrome, it is crucial to note that only 1 in every 1000 people with this condition eventually develops GBS, indicating a minimal risk for any individual.
• Infection with C. fetus may be fatal for individuals with chronic compensated conditions such as cirrhosis or diabetes mellitus.
consequences • The primary postinfectious consequences of Campylobacter enteritis in immunocompetent individuals are reactive arthritis and Guillain–Barré syndrome, as previously mentioned.
• • • • •
Campylobacter infections can be fatal in immunocompromised persons.
Campylobacter jejuni may induce septic abortion.
Reports of C. jejuni infections presenting with acute cholecystitis, pancreatitis, and cystitis have been sporadic.
Campylobacter jejuni has been linked to an intestinal immunoproliferative disease characterized by malabsorption and protein-losing enteropathy.
C. fetal infections demonstrate a preference for arterial locations; vascular necrosis is observed in patients with endocarditis and pericarditis.
CNS infections caused by C. fetus manifest in neonates and
individuals of mature age. The prognosis for premature infants is unfavorable; nonetheless, certain full-term neonates have survived infections. The infection presents as meningoencephalitis characterized by polymorphonuclear pleocytosis in the cerebrospinal fluid.
In immunocompromised patients, particularly those with AIDS, bacteremia caused by the "atypical" Campylobacter species occurs rather frequently and may persist indefinitely in the absence of antibiotic treatment.
